The Covid-19 Arterial Thromboembolic Complications: From Inflammation To Immunothrombosis Through Anti-Phospholipid Autoantibodies

Roncati L, Manenti A, Manco G, Farinetti A, Mattioli A.

COVID-19 and Inflammatory Bowel Disease: Lessons Learned, Practical Recommendations, and Unanswered Questions

Ungaro RC, Kappelman MD, Rubin DT, Colombel JF.

Multisystem Inflammatory Syndrome in Children: Clinical Features and Management-Intensive Care Experience from a Pediatric Public Hospital in Western India

Shobhavat L, Solomon R, Rao S, Bhagat I, Prabhu S, Prabhu S, Chandrakar M, Bodhanwala M.

Multisystem Inflammatory Syndrome of Children Related to SARS-CoV-2: A Novel Experience in Children with a Novel Virus

Bhattacharyya P.

Peripheral inflammation and blood-brain barrier disruption: effects and mechanisms

Huang X, Hussain B, Chang J.

Effects of the COVID-19 Pandemic on Anti-vascular Endothelial Growth Factor Treatment in China

Yang KB, Feng H, Zhang H.

Impact of corticosteroids and immunosuppressive therapies on symptomatic SARS-CoV-2 infection in a large cohort of patients with chronic inflammatory arthritis

Favalli EG, Bugatti S, Klersy C, Biggioggero M, Rossi S, De Lucia O, Bobbio-Pallavicini F, Murgo A, Balduzzi S, Caporali R, Montecucco C.

A retrospective matched cohort single-center study evaluating outcomes of COVID-19 and the impact of immunomodulation on COVID-19-related cytokine release syndrome in solid organ transplant recipients

Ringer M, Azmy V, Kaman K, Tang D, Cheung H, Azar MM, Price C, Malinis M.

Complexities of the COVID-19 vaccine and multisystem inflammatory syndrome in children

Blumenthal JA, Burns JP.

Severe acute respiratory syndrome coronavirus 2-induced multisystem inflammatory syndrome in children

Feng Z, Bao Y, Yang Y, Zheng Y, Shen K.

Correction to: A randomized, open-label, adaptive, proof-of-concept clinical trial of modulation of host thromboinflammatory response in patients with COVID-19: the DAWn-Antico study

Vanassche T, Engelen MM, Van Thillo Q, Wauters J, Gunst J, Wouters C, Vandenbriele C, Rex S, Liesenborghs L, Wilmer A, Meersseman P, Van den Berghe G, Dauwe D, Verbeke G, Thomeer M, Fivez T, Mesotten D, Ruttens D, Heytens L, Dapper I, Tuyls S, De Tavernier B, Verhamme P; DAWn consortium members.

Calming the (Cytokine) Storm: Dimethyl Fumarate as a Therapeutic Candidate for COVID-19

Timpani CA, Rybalka E.

Disturbances of the hemostasis system and expression of inflammatory reaction in patients with new coronaviral pneumonia

Presnyakova MV, Galova EA, Sosnina LN, Popovicheva AN, Lyubavina NA, Kostina OV, Kuznetsova VL, Karyakin NN.

SARS-CoV-2 proteases PLpro and 3CLpro cleave IRF3 and critical modulators of inflammatory pathways (NLRP12 and TAB1): implications for disease presentation across species

Moustaqil M, Ollivier E, Chiu HP, Van Tol S, Rudolffi-Soto P, Stevens C, Bhumkar A, Hunter DJB, Freiberg AN, Jacques D, Lee B, Sierecki E, Gambin Y.

Extracorporeal Membrane Oxygenation for COVID-19-Associated Multisystem Inflammatory Syndrome in a 5-year-old

Schwartz SP, Walker TC, Kihlstrom M, Isani M, Smith MM, Smith RL, McLean SE, Clement KC, Phillips MR.

ADHERENCE TO INTRAVENOUS BIOLOGICAL TREATMENT IN INFLAMMATORY BOWEL DISEASE PATIENTS DURING THE COVID-19 PANDEMIC

SuÁrez Ferrer C, Perez Robles T, Martin-Arranz MD.

Views of patients with inflammatory bowel disease during the COVID-19 pandemic: ACCU survey results

Fernández Álvarez P, Belvis Jiménez M, Maldonado Pérez B, Castro Laria L, Caunedo Álvarez Á, Rodríguez de Los Ríos JL, Argüelles-Arias F.

Effects of Prone Ventilation on Oxygenation, Inflammation, and Lung Infiltrates in COVID-19 Related Acute Respiratory Distress Syndrome: A Retrospective Cohort Study

Khullar R, Shah S, Singh G, Bae J, Gattu R, Jain S, Green J, Anandarangam T, Cohen M, Madan N, Prasanna P.

Incidence and severeness of COVID-19 hospitalisation in patients with inflammatory rheumatic disease: a nationwide cohort study from Denmark

Cordtz R, Lindhardsen J, Soussi BG, Vela J, Uhrenholt L, Westermann R, Kristensen S, Nielsen H, Torp-Pedersen C, Dreyer L.

Risk mitigating behaviours in people with inflammatory skin and joint disease during the COVID-19 pandemic differ by treatment type: a cross-sectional patient survey

Mahil SK, Yates M, Langan SM, Yiu ZZN, Tsakok T, Dand N, Mason KJ, McAteer H, Meynell F, Coker B, Vincent A, Urmston D, Vesty A, Kelly J, Lancelot C, Moorhead L, Bachelez H, Bruce IN, Capon F, Contreras CR, Cope AP, De La Cruz C, Di Meglio P, Gisondi P, Hyrich K, Jullien D, Lambert J, Marzo-Ortega H, McKinnes I, Naldi L, Norton S, Puig L, Sengupta R, Spuls P, Torres T, Warren RB, Waweru H, Weinman J, Griffiths CM, Barker JN, Brown MA, Galloway JB, Smith CH.

Severe Acute Respiratory Syndrome Coronavirus 2 Placental Infection and Inflammation Leading to Fetal Distress and Neonatal Multi-Organ Failure in an Asymptomatic Woman

Schoenmakers S, Snijder P, Verdijk RM, Kuiken T, Kamphuis SSM, Koopman LP, Krasemann TB, Rousian M, Broekhuizen M, Steegers EAP, Koopmans MPG, Fraaij PLA, Reiss IKM.

Treatment of cytokine storm syndrome with IL-1 receptor antagonist anakinra in a patient with ARDS caused by COVID-19 infection: A case report

Kaps L, Labenz C, Grimm D, Schwarting A, Galle PR, Schreiner O.

Plasma exchange for COVID-19 thrombo-inflammatory disease

Arulkumaran N, Thomas M, Brealey D, Alwan F, Singh D, Lunn M, Welch A, Clark S, Raith E, Reddy U, Low R, Leverett D, Singer M, Scully M.

The Role of MSC Therapy in Attenuating the Damaging Effects of the Cytokine Storm Induced by COVID-19 on the Heart and Cardiovascular System

Ellison-Hughes GM, Colley L, O'Brien KA, Roberts KA, Agbaedeng TA, Ross MD.

Treatment of Rare Inflammatory Kidney Diseases: Drugs Targeting the Terminal Complement Pathway

Ort M, Dingemanse J, van den Anker J, Kaufmann P.

A Network-Based Analysis Reveals the Mechanism Underlying Vitamin D in Suppressing Cytokine Storm and Virus in SARS-CoV-2 Infection

Ahmed F.

Nutraceutical Targeting of Inflammation-Modulating microRNAs in Severe Forms of COVID-19: A Novel Approach to Prevent the Cytokine Storm

Desjarlais M, Wirth M, Lahaie I, Ruknudin P, Hardy P, Rivard A, Chemtob S.

Hypertension delays viral clearance and exacerbates airway hyperinflammation in patients with COVID-19

Trump S, Lukassen S, Anker MS, Chua RL, Liebig J, Thürmann L, Corman VM, Binder M, Loske J, Klasa C, Krieger T, Hennig BP, Messingschlager M, Pott F, Kazmierski J, Twardziok S, Albrecht JP, Eils J, Hadzibegovic S, Lena A, Heidecker B, Bürgel T, Steinfeldt J, Goffinet C, Kurth F, Witzenrath M, Völker MT, Müller SD, Liebert UG, Ishaque N, Kaderali L, Sander LE, Drosten C, Laudi S, Eils R, Conrad C, Landmesser U, Lehmann I.

Cytokine release syndrome: inhibition of pro-inflammatory cytokines as a solution for reducing COVID-19 mortality

Moradian N, Gouravani M, Salehi MA, Heidari A, Shafeghat M, Hamblin MR, Rezaei N.

Could natural products modulate early inflammatory responses, preventing acute respiratory distress syndrome in COVID-19-confirmed patients?

Amaral-Machado L, Oliveira WN, Rodrigues VM, Albuquerque NA, Alencar ÉN, Egito EST.

Cytokine storm induced by SARS-CoV-2 infection: The spectrum of its neurological manifestations

Thepmankorn P, Bach J, Lasfar A, Zhao X, Souayah S, Chong ZZ, Souayah N.

Effects of vitamin D on macrophages and myeloid-derived suppressor cells (MDSCs) hyperinflammatory response in the lungs of COVID-19 patients

Kloc M, Ghobrial RM, Lipińska-Opałka A, Wawrzyniak A, Zdanowski R, Kalicki B, Kubiak JZ.

Better prognosis in females with severe COVID-19 pneumonia: possible role of inflammation as potential mediator

Mussini C, Cozzi-Lepri A, Menozzi M, Meschiari M, Franceschini E, Rogati C, Cuomo G, Bedini A, Iadisernia V, Volpi S, Milic J, Tonelli R, Brugioni L, Pietrangelo A, Girardis M, Cossarizza A, Clini E, Guaraldi G; Modena Covid‐19 Working Group (MoCo19); Office of information and communication technologies of Policlinico di Modena.

A new storm on the horizon in COVID-19: Bradykinin-induced vascular complications

McCarthy CG, Wilczynski S, Wenceslau CF, Webb RC.

Targeting inflammatory cytokine storm to fight against COVID-19 associated severe complications

Hirawat R, Saifi MA, Godugu C.

Strategies to DAMPen COVID-19-mediated lung and systemic inflammation and vascular injury

Bime C, Casanova NG, Nikolich-Zugich J, Knox KS, Camp SM, Garcia JGN.

Electrocardiographic changes in children with multisystem inflammation associated with COVID-19

Regan W, O'Byrne L, Stewart K, Miller O, Pushparajah K, Theocharis P, Wong J, Rosenthal E.

Plasmapheresis reduces cytokine and immune cell levels in COVID-19 patients with acute respiratory distress syndrome (ARDS)

Hashemian SM, Shafigh N, Afzal G, Jamaati H, Tabarsi P, Marjani M, Malekmohammad M, Mortazavi SM, Khoundabi B, Mansouri D, Moniri A, Hajifathali A, Roshandel E, Mortaz E, Adcock IM.

[Improving parasympathetic functioning to contain the inflammatory response of COVID-19 infection]

Ferrer MH, Severin R, Lefort H, Jacob S, Trousselard M.

Phosphatidylserine inside out: a possible underlying mechanism in the inflammation and coagulation abnormalities of COVID-19

Argañaraz GA, Palmeira JDF, Argañaraz ER.

Heart failure and COVID-19: synergism of two inflammatory conditions?

Khan E.

Association of ACEI/ARB, inflammatory cytokines, and antiviral drugs with liver dysfunction in patients with hypertension and COVID-19

Xiang D, Ren X, Chen Q, Yu H, Li X, Liu D.

Correspondence on 'Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases'

Aydin SZ, Hepworth E, Tugwell P.

Response to: 'Correspondence on 'Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases'' by Aydin et al

Freites Nuñez DD, Leon L, Mucientes A, Rodriguez-Rodriguez L, Font Urgelles J, Madrid García A, Colomer JI, Jover JA, Fernandez-Gutierrez B, Abasolo L.

Tetracyclines in COVID-19 patients quarantined at home: Literature evidence supporting real-world data from a multicenter observational study targeting inflammatory and infectious dermatoses

Gironi LC, Damiani G, Zavattaro E, Pacifico A, Santus P, Pigatto PDM, Cremona O, Savoia P.

The Perfect Storm: Hidden Risk of Child Maltreatment During the Covid-19 Pandemic

Rodriguez CM, Lee SJ, Ward KP, Pu DF.

Vascular Endothelial Glycocalyx Damage in COVID-19

Yamaoka-Tojo M.

COVID-19 in patients with systemic lupus erythematosus: lessons learned from the inflammatory disease

Fernandez-Ruiz R, Paredes JL, Niewold TB.

Outcomes of Renal Transplant Recipients With SARS-CoV-2 Infection in the Eye of the Storm: A Comparative Study With Waitlisted Patients

Mohamed IH, Chowdary PB, Shetty S, Sammartino C, Sivaprakasam R, Lindsey B, Thuraisingham R, Yaqoob MM, Khurram MA.

Effects of Intestinal Fungi and Viruses on Immune Responses and Inflammatory Bowel Diseases

Iliev ID, Cadwell K.

Thrombophilia in Pediatric Patients with Multisystem Inflammatory Syndrome in Children Secondary to Coronavirus Disease 2019 Supported on Extracorporeal Membrane Oxygenation

Minen F, Hands C, Mustafa MR, Pienaar A, Lillie J.

Potential roles of mitochondrial cofactors in the adjuvant mitigation of proinflammatory acute infections, as in the case of sepsis and COVID-19 pneumonia

Pagano G, Manfredi C, Pallardó FV, Lyakhovich A, Tiano L, Trifuoggi M.

Pediatric Inflammatory Multisystem Syndrome and Rheumatic Diseases During SARS-CoV-2 Pandemic

Schvartz A, Belot A, Kone-Paut I.

COVID-19 and Neutrophils: The Relationship between Hyperinflammation and Neutrophil Extracellular Traps

Borges L, Pithon-Curi TC, Curi R, Hatanaka E.

Anti-inflammatory substances from onions could be an option for treatment of COVID-19 - a hypothesis

Dorsch W, Ring J.

Consequences and management of COVID-19 on the care activity of an inflammatory Bowel Disease unit

El Hajra I, Calvo M, Santos Pérez E, Blanco Rey S, González Partida I, Matallana V, González-Lama Y, Vera MI.

Delayed diffuse inflammatory myocardial damage in a child with a history of systemic inflammatory syndrome related to COVID-19

Mahdavi M, Houshmand G, Pouraliakbar H, Mortaz Hejri G.

Hyperinflammation and Immune Response Generation in COVID-19

Mishra KP, Singh AK, Singh SB.

Spread of OXA-48-producing Klebsiella pneumoniae among COVID-19-infected patients: The storm after the storm

García-Meniño I, Forcelledo L, Rosete Y, García-Prieto E, Escudero D, Fernández J.

Possible immunity, inflammation, and oxidative stress mechanisms of Alzheimer's disease in COVID-19 patients

Wang H, Qin R, Zhang J, Chen Y.

COVID-19 associated arterial ischaemic stroke and multisystem inflammatory syndrome in children: a case report

Tiwari L, Shekhar S, Bansal A, Kumar S.

Late-onset myocardial infarction and autoimmune haemolytic anaemia in a COVID-19 patient without respiratory symptoms, concomitant with a paradoxical increase in inflammatory markers: a case report

Pelle MC, Tassone B, Ricchio M, Mazzitelli M, Davoli C, Procopio G, Cancelliere A, La Gamba V, Lio E, Matera G, Quirino A, Barreca GS, Trecarichi EM, Torti C; IDTM UMG COVID-19 Group.

Investigation of Genetic Variations of IL6 and IL6R as Potential Prognostic and Pharmacogenetics Biomarkers: Implications for COVID-19 and Neuroinflammatory Disorders

Strafella C, Caputo V, Termine A, Barati S, Caltagirone C, Giardina E, Cascella R.

A nuclear factor kappa B reporter cell line used to evaluate ex vivo the net inflammatory effect of plasma samples from patients with rheumatoid arthritis, psoriasis, or COVID-19

Wagner L, Haefeli WE, Merle U, Lorenz HM, Hohmann N, Weiss J, Theile D.

Role of Host Immune and Inflammatory Responses in COVID-19 Cases with Underlying Primary Immunodeficiency: A Review

Liu BM, Hill HR.

Interleukin 6 in inflammation, autoimmunity and cancer

Hirano T.

Cytokine storms caused by novel coronavirus 2019 and treatment for cardiac injury

Zhang DM, Chen SL.

Serum-soluble ST2 as a novel biomarker reflecting inflammatory status and illness severity in patients with COVID-19

Zeng Z, Hong XY, Li Y, Chen W, Ye G, Li Y, Luo Y.

Effects of curcumin-piperine co-supplementation on clinical signs, duration, severity, and inflammatory factors in patients with COVID-19: a structured summary of a study protocol for a randomised controlled trial

Miryan M, Bagherniya M, Sahebkar A, Soleimani D, Rouhani MH, Iraj B, Askari G.

[Association of D-dimer, inflammatory markers, cytokines abnormality, and disease severity in COVID-19 severe/critical patients in Wuhan]

Zhang J, Gao XL, Li DJ, Jiang Y, Liu Y, Pang L, Xu D, Yang LH.

Increased Intracranial Pressure in the Setting of Multisystem Inflammatory Syndrome in Children, Associated With COVID-19

Baccarella A, Linder A, Spencer R, Jonokuchi AJ, King PB, Maldonado-Soto A, Boneparth A, Hooe BS, Schweickert AJ, Carlin RF, Kingery F, Vargas WS, Sewell TB, Silver WG.

Influenza infection, SARS, MERS and COVID-19: Cytokine storm - The common denominator and the lessons to be learned

Ryabkova VA, Churilov LP, Shoenfeld Y.

[COVID-19-associated hyperinflammatory state in a 15-year-old female patient]

Blink M, Buddingh' EP, Filippini LHPM, Brinkman DMC, Joosten SA, Klein RH.

COVID-19 and patients with immune-mediated inflammatory diseases undergoing pharmacological treatments: a rapid living systematic review

Rocha APD, Atallah ÁN, Pinto ACPN, Rocha-Filho CR, Milby KM, Civile VT, Carvas Junior N, Reis FSA, Ferla LJ, Ramalho GS, Trevisani GFM, Puga MEDS, Trevisani VFM.

Proposed recommendations for antithrombotic prophylaxis for children and adolescents with severe infection and/or multisystem inflammatory syndrome caused by SARS-CoV-2

Carneiro JDA, Ramos GF, de Carvalho WB, Johnston C, Delgado AF.

Inflammatory Bowel Disease Management in a Romanian Tertiary Gastroenterology Center: Challenges of the COVID-19 Pandemic

Vadan R, Iacob R, Costache R, Stroie T, Saizu IA, Iacob S, Gheorghe L, Diculescu M, Gheorghe C.

Impact of COVID-19 on the Healthcare of Patients With Inflammatory Bowel Disease: A Comparison Between Epicenter vs. Non-epicenter Areas

Qiu Y, Zhang YF, Zhu LR, He JS, Tan JY, Tan ND, Lin SN, Lin XQ, Ghosh S, Chen MH, Mao R.

COVID-19 in Children: A Review and Parallels to Other Hyperinflammatory Syndromes

Hobbs CV, Khaitan A, Kirmse BM, Borkowsky W.

Hyperinflammation in Two Severe Acute Respiratory Syndrome Coronavirus 2-Infected Adolescents Successfully Treated With the Interleukin-1 Inhibitor Anakinra and Glucocorticoids

Calò Carducci FI, De Ioris MA, Agrati C, Carsetti R, Perrotta D, D'Argenio P, De Benedetti F, Notari S, Rossi P, Campana A.

Controlling Cytokine Storm Is Vital in COVID-19

Tang L, Yin Z, Hu Y, Mei H.

Pre-Existing Cytokine and NLRP3 Inflammasome Activation and Increased Vascular Permeability in Diabetes: A Possible Fatal Link With Worst COVID-19 Infection Outcomes?

Lambadiari V, Kousathana F, Raptis A, Katogiannis K, Kokkinos A, Ikonomidis I.

COVID-19: Hyperinflammatory Syndrome and Hemoadsorption with CytoSorb

Masmouei B, Harorani M, Bazrafshan MR, Karimi Z.

Clinical outcomes and inflammatory marker levels in patients with Covid-19 and obesity at an inner-city safety net hospital

Mostaghim A, Sinha P, Bielick C, Knudsen S, Beeram I, White LF, Apovian C, Sagar M, Hochberg NS.

Lipid droplets fuel SARS-CoV-2 replication and production of inflammatory mediators

Dias SSG, Soares VC, Ferreira AC, Sacramento CQ, Fintelman-Rodrigues N, Temerozo JR, Teixeira L, Nunes da Silva MA, Barreto E, Mattos M, de Freitas CS, Azevedo-Quintanilha IG, Manso PPA, Miranda MD, Siqueira MM, Hottz ED, Pão CRR, Bou-Habib DC, Barreto-Vieira DF, Bozza FA, Souza TML, Bozza PT.

Are mesenchymal stem cells and derived extracellular vesicles valuable to halt the COVID-19 inflammatory cascade? Current evidence and future perspectives

Monguió-Tortajada M, Bayes-Genis A, Rosell A, Roura S.

Mucocutaneous disease and related clinical characteristics in hospitalized children and adolescents with COVID-19 and multisystem inflammatory syndrome in children

Rekhtman S, Tannenbaum R, Strunk A, Birabaharan M, Wright S, Garg A.

Can Natural Polyphenols Help in Reducing Cytokine Storm in COVID-19 Patients?

Giovinazzo G, Gerardi C, Uberti-Foppa C, Lopalco L.

Challenges and Opportunities from Targeting Inflammatory Responses to SARS-CoV-2 Infection: A Narrative Review

Lariccia V, Magi S, Serfilippi T, Toujani M, Gratteri S, Amoroso S.

Transcriptional Profiling of Immune and Inflammatory Responses in the Context of SARS-CoV-2 Fungal Superinfection in a Human Airway Epithelial Model

Nicolas de Lamballerie C, Pizzorno A, Fouret J, Szpiro L, Padey B, Dubois J, Julien T, Traversier A, Dulière V, Brun P, Lina B, Rosa-Calatrava M, Terrier O.

[A surgically relevant summary of the addendum to the S3 guidelines of the DGVS on Crohn's disease and ulcerative colitis : Treatment of chronic inflammatory bowel diseases in the COVID-19 pandemic]

Grunert PC, Dignass A, Kucharzik T, Stallmach A, Sturm A, Schmidt C.

Scoring cytokine storm by the levels of MCP-3 and IL-8 accurately distinguished COVID-19 patients with high mortality

Chen L, Wang G, Tan J, Cao Y, Long X, Luo H, Tang Q, Jiang T, Wang W, Zhou J.

Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study'

Calvo-Aranda E, Cañamares-Orbis I, Novella-Navarro M, Martinez-Alcala A, Ortega de la O MDC, Escobar-Rodriguez I, Sanchez-Aranda FM.

Response to: 'Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19- associated cytokine storm syndrome: results of the CHIC study'' by Calvo-Aranda et al

Ramiro S, Mostard R, Landewé RB.

[Paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2]

Al-Mousawi A, Mogensen TH.

Corticosteroid therapy is associated with improved outcome in critically ill COVID-19 patients with hyperinflammatory phenotype

Chen H, Xie J, Su N, Wang J, Sun Q, Li S, Jin J, Zhou J, Mo M, Wei Y, Chao Y, Hu W, Du B, Qiu H.

Integrated Bioinformatics Analysis Reveals Key Candidate Genes and Cytokine Pathways Involved in COVID-19 After Rhinovirus Infection in Asthma Patients

Dai W, Cao D, Zhang W, Wei Y, Ding D, Li B, Gao Y, Zhao L, Jiang Y, Kong X.

Extracorporeal Membrane Oxygenation and Inflammation in COVID-19

Supady A, Bode C, Duerschmied D.

Does inflammation link stress to poor COVID-19 outcome?

Lamontagne SJ, Pizzagalli DA, Olmstead MC.

The psychological impact of the COVID-19 pandemic on Dutch people with and without an inflammatory rheumatic disease

Koppert TY, Jacobs JWG, Geenen R.

Recombinant ACE2 Expression Is Required for SARS-CoV-2 To Infect Primary Human Endothelial Cells and Induce Inflammatory and Procoagulative Responses

Nascimento Conde J, Schutt WR, Gorbunova EE, Mackow ER.

The evolving obesity challenge: Targeting the vagus nerve and the inflammatory reflex in the response

Pavlov VA.

Insights on Kawasaki disease and multisystem inflammatory syndrome; relationship with COVID-19 infection

Calcaterra G, Mehta JL, Fanos V, Bassareo PP.

The deregulated immune reaction and cytokines release storm (CRS) in COVID-19 disease

Pasrija R, Naime M.

COVID-19-related myocarditis and cholinergic anti-inflammatory pathways

Liu W, Liu Z, Li YC.

Could Dietary Factors Reduce COVID-19 Mortality Rates? Moderating the Inflammatory State

Eiser AR.

Post-infectious inflammatory disease in MIS-C features elevated cytotoxicity signatures and autoreactivity that correlates with severity

Ramaswamy A, Brodsky NN, Sumida TS, Comi M, Asashima H, Hoehn KB, Li N, Liu Y, Shah A, Ravindra NG, Bishai J, Khan A, Lau W, Sellers B, Bansal N, Sparks R, Unterman A, Habet V, Rice AJ, Catanzaro J, Chandnani H, Lopez M, Kaminski N, Dela Cruz CS, Tsang JS, Wang Z, Yan X, Kleinstein SH, van Dijk D, Pierce RW, Hafler DA, Lucas CL.

Topoisomerase 1 inhibition therapy protects against SARS-CoV-2-induced inflammation and death in animal models

Yuin Ho JS, Wing-Yee Mok B, Campisi L, Jordan T, Yildiz S, Parameswaran S, Wayman JA, Gaudreault NN, Meekins DA, Indran SV, Morozov I, Trujillo JD, Fstkchyan YS, Rathnasinghe R, Zhu Z, Zheng S, Zhao N, White K, Ray-Jones H, Malysheva V, Thiecke MJ, Lau SY, Liu H, Junxia Zhang A, Chak-Yiu Lee A, Liu WC, Aydillo T, Salom Melo B, Guccione E, Sebra R, Shum E, Bakker J, Kaufman DA, Moreira AL, Carossino M, Balasuriya UBR, Byun M, Miraldi ER, Albrecht RA, Schotsaert M, Garcia-Sastre A, Chanda SK, Jeya

Varying Presentations of Multisystem Inflammatory Syndrome Temporarily Associated with COVID-19

Krikilion J, Nuyttens L, Daelemans S, François K, Mauel R, De Wolf D, van Berlaer G.

Abdominal Imaging Findings in Critically Ill Children With Multisystem Inflammatory Syndrome Associated With COVID-19

Morparia K, Park MJ, Kalyanaraman M, McQueen D, Bergel M, Phatak T.

Paediatric inflammatory multisystem syndrome temporally associated with COVID-19: a new virus and a new case presentation

Makiello P, Svirpliene S, Finlay L, McKnight J.

A randomized, open-label, adaptive, proof-of-concept clinical trial of modulation of host thromboinflammatory response in patients with COVID-19: the DAWn-Antico study

Vanassche T, Engelen MM, Van Thillo Q, Wauters J, Gunst J, Wouters C, Vandenbriele C, Rex S, Liesenborghs L, Wilmer A, Meersseman P, Van den Berghe G, Dauwe D, Verbeke G, Thomeer M, Fivez T, Mesotten D, Ruttens D, Heytens L, Dapper I, Tuyls S, De Tavernier B, Verhamme P; DAWn consortium members.

COVID-19, microthromboses, inflammation, and platelet activating factor

Demopoulos C, Antonopoulou S, Theoharides TC.

Mucocutaneous Manifestations of Multisystem Inflammatory Syndrome in Children During the COVID-19 Pandemic

Young TK, Shaw KS, Shah JK, Noor A, Alperin RA, Ratner AJ, Orlow SJ, Betensky RA, Shust GF, Kahn PJ, Oza VS.

SARS-CoV-2 Spike protein binds to bacterial lipopolysaccharide and boosts proinflammatory activity

Petruk G, Puthia M, Petrlova J, Samsudin F, Strömdahl AC, Cerps S, Uller L, Kjellström S, Bond PJ, Schmidtchen A.

[COVID-19-associated multisystem inflammatory syndrome in children: case series at a pediatric hospital in Peru]

Coll-Vela LE, Zamudio-Aquise MK, Nuñez-Paucar H, Bernal-Mancilla RR, Schult-Montoya SC, Ccorahua-De La Paz M, Huby-Muñoz CL, Castillo-Torres CF, Candela-Herrera JL, Aranda-Paniora F, Rojas-Galarza RA.

Anti-inflammatory therapy for COVID-19 infection: the case for colchicine

Reyes AZ, Hu KA, Teperman J, Wampler Muskardin TL, Tardif JC, Shah B, Pillinger MH.

Hypoxia: A key feature of COVID-19 launching activation of HIF-1 and cytokine storm

Jahani M, Dokaneheifard S, Mansouri K.

The Systemic Inflammation Index on Admission Predicts In-Hospital Mortality in COVID-19 Patients

Fois AG, Paliogiannis P, Scano V, Cau S, Babudieri S, Perra R, Ruzzittu G, Zinellu E, Pirina P, Carru C, Arru LB, Fancellu A, Mondoni M, Mangoni AA, Zinellu A.

Association of Inflammatory Markers with Mortality in COVID-19 Infection

Arshad AR, Khan I, Shahzad K, Arshad M, Haider SJ, Aslam MJ.

Eye Diseases Direct Interest to Complement Pathway and Macrophages as Regulators of Inflammation in COVID-19

Jager MJ, Seddon JM.

Inflammatory cytokine depletion in severe coronavirus disease 2019 infectious pneumonia: A case report

Yang B, Yang J, Zhou L, Xue C, Li H, Hu W, Liu N.

Multisystem Inflammatory Syndrome in Adults: Coming Into Focus

Tenforde MW, Morris SB.

COVID-19-Associated Acute Kidney Injury and Quantified Protein Catabolic Rate: A Likely Effect of Cytokine Storm on Muscle Protein Breakdown

Uribarri J, El Shamy O, Sharma S, Winston J.

Is there a place for anti-inflammatory therapy in COVID-19?

Yew WW, Chang KC, Chan DP.

Modeling and simulations of CoViD-19 molecular mechanism induced by cytokines storm during SARS-CoV2 infection

Yu Z, Ellahi R, Nutini A, Sohail A, Sait SM.

Inflammatory markers are poorly predictive of clinical outcomes among hospitalized patients with COVID-19

Barrett B, Pamphile S, Yang F, Naeem F, Kim J, Annam J, Borczuk R, Yellin S, Bass C, Fowler S, Mosheyev M, Mayer YJ, Friedman BW.

The interplay between inflammatory pathways and COVID-19: A critical review on pathogenesis and therapeutic options

Choudhary S, Sharma K, Silakari O.

Systemic microvascular endothelial dysfunction and disease severity in COVID-19 patients: Evaluation by laser Doppler perfusion monitoring and cytokine/chemokine analysis

Sabioni L, De Lorenzo A, Lamas C, Muccillo F, Castro-Faria-Neto HC, Estato V, Tibirica E.

Baricitinib treatment resolves lower-airway macrophage inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques

Hoang TN, Pino M, Boddapati AK, Viox EG, Starke CE, Upadhyay AA, Gumber S, Nekorchuk M, Busman-Sahay K, Strongin Z, Harper JL, Tharp GK, Pellegrini KL, Kirejczyk S, Zandi K, Tao S, Horton TR, Beagle EN, Mahar EA, Lee MYH, Cohen J, Jean SM, Wood JS, Connor-Stroud F, Stammen RL, Delmas OM, Wang S, Cooney KA, Sayegh MN, Wang L, Filev PD, Weiskopf D, Silvestri G, Waggoner J, Piantadosi A, Kasturi SP, Al-Shakhshir H, Ribeiro SP, Sekaly RP, Levit RD, Estes JD, Vanderford TH, Schinazi RF, Bosinger SE,

Synergism of TNF-α and IFN-γ Triggers Inflammatory Cell Death, Tissue Damage, and Mortality in SARS-CoV-2 Infection and Cytokine Shock Syndromes

Karki R, Sharma BR, Tuladhar S, Williams EP, Zalduondo L, Samir P, Zheng M, Sundaram B, Banoth B, Malireddi RKS, Schreiner P, Neale G, Vogel P, Webby R, Jonsson CB, Kanneganti TD.

Coronavirus Disease 2019 (COVID-19)-Related Multisystem Inflammatory Syndrome in a Pregnant Woman

Gulersen M, Staszewski C, Grayver E, Tam Tam H, Gottesman E, Isseroff D, Rochelson B, Bonanno C.

Multisystem inflammatory syndrome in children

Soma VL, Shust GF, Ratner AJ.

American College of Rheumatology Clinical Guidance for Pediatric Patients with Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with SARS-CoV-2 and Hyperinflammation in COVID-19. Version 2

Henderson LA, Canna SW, Friedman KG, Gorelik M, Lapidus SK, Bassiri H, Behrens EM, Ferris A, Kernan KF, Schulert GS, Seo P, Son MBF, Tremoulet AH, Yeung RSM, Mudano AS, Turner AS, Karp DR, Mehta JJ.

The risk for severe COVID 19 in patients with autoimmune and/or inflammatory diseases: First wave lessons

Druyan A, Lidar M, Brodavka M, Levy I, Barzilai A, Pavlotsky F.

Association between SARS-CoV-2 infection and Kawasaki-like multisystem inflammatory syndrome: a retrospective matched case-control study, Paris, France, April to May 2020

Toubiana J, Levy C, Allali S, Jung C, Leruez-Ville M, Varon E, Bajolle F, Ouldali N, Chareyre J, Béchet S, Elbez A, Casanova JL, Chalumeau M, Cohen R, Cohen JF.

Can Cytokine Serum Levels Be Useful With Kidney Transplantation and COVID-19?

Adani GL, Pravisani R, Fabris M, Avital I, Curcio F, Baccarani U.

The potential role of inflammation reaction in COVID-19 related posttraumatic stress disorder

Jiang Y, Huang Z, Mi L, Zhou Y.

Cytokine ranking via mutual information algorithm correlates cytokine profiles with presenting disease severity in patients with COVID-19

Huntington KE, Louie AD, Lee CG, Elias JA, Ross EA, El-Deiry WS.

Does Nicotine Prevent Cytokine Storms in COVID-19?

Dratcu L, Boland X.

Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients

FAI2R /SFR/SNFMI/SOFREMIP/CRI/IMIDIATE consortium and contributors.

Reply to "Antiviral and anti-inflammatory properties of ivermectinand its potential use in COVID-19"

Accinelli RA, Portmann-Baracco A, Bryce-Alberti M.

Early Cytokine Removal in Critical COVID-19 Patients with Extracorporeal Therapies (HA-380 plus High Volume Hemofiltration) May Prevent Progression of Acute Respiratory Distress Syndrome: Case Report

Ramírez-Guerrero G, Torres Cifuentes V, Baghetti Hernández R, Villagrán Cortés F, Rojas Doll S, Oliva Alarcón R, Lucero Córdova C, Flores Fernandez P, Garay Coloma O.

Interleukin-6 signaling blockade treatment for cytokine release syndrome in COVID-19 (Review)

Chen JJ, Zhang LN, Hou H, Xu L, Ji K.

Corrigendum to "At the height of the storm: Healthcare staff's health conditions and job satisfaction and their associated predictors during the epidemic peak of COVID-19" [Brain Behav. Immun. 87 (2020) 144-146]

Zhang SX, Liu J, Afshar Jahanshahi A, Nawaser K, Yousefi A, Li J, Sun S.

Neurosurgeons on the front line: experience from the center of the storm in Italy

Bernucci C, Fanti A, Veiceschi P, Costi E, Sicignano AM, Brembilla C.

LMWF5A suppresses cytokine release by modulating select inflammatory transcription factor activity in stimulated PBMC

Thomas G, Frederick E, Thompson L, Bar-Or R, Mulugeta Y, Hausburg M, Roshon M, Mains C, Bar-Or D.

Impairment of the cholinergic anti-inflammatory pathway in older subjects with severe COVID-19

Pomara N, Imbimbo BP.

Empiric antibiotics in management of inpatient pregnant women infected with coronavirus disease 2019 (COVID-19): Focusing on inflammation and preterm labor

Norooznezhad AH, Hantoushzadeh S, Shamshirsaz AA.

Distinguishing between typical Kawasaki disease and multisystem inflammatory syndrome in children (MIS-C) associated with SARS-CoV-2

Yeo WS, Ng QX.

Heme oxygenase-1 (HO-1) cytoprotective pathway: A potential treatment strategy against coronavirus disease 2019 (COVID-19)-induced cytokine storm syndrome

Rossi M, Piagnerelli M, Van Meerhaeghe A, Zouaoui Boudjeltia K.

Can hyperbaric oxygen safely serve as an anti-inflammatory treatment for COVID-19?

Kjellberg A, De Maio A, Lindholm P.

Gamma-oryzanol as a possible PPAR-γ agonist in adipose tissue may represents a coadjutant therapeutic to prevent cytokine storm in COVID-19 obese patients

Francisqueti-Ferron FV, Garcia JL, Togneri Ferron AJ, Nakandakare-Maia ET, Gregolin CS, Paixão das Chagas Silva J, Carolo Dos Santos K, Colombo Lo ÂT, Siqueira JS, de Mattei L, Henrique de Paula B, Sarzi F, Vágula de Almeida Silva CC, Moreto F, Costa MR, Lucia A Ferreira A, Minatel IO, Correa CR.

Frequency and severity of COVID-19 in patients treated with biological disease-modifying anti-rheumatic drugs for inflammatory rheumatic disease: a cross-sectional study

Lohse A, Bossert M, Bozgan AM, Charpentier A, Guillochon C, Bourgoin C, Balblanc JC, Conrozier T.

Persistent viral activity, cytokine storm, and lung fibrosis in a case of severe COVID-19

Xu G, Liu Y, Liao M, Gou J, Wang X, Yuan J, Liu W, Zhou G, Zhang S, Liu L, Zhang Z.

Race/Ethnicity Among Children With COVID-19-Associated Multisystem Inflammatory Syndrome

Lee EH, Kepler KL, Geevarughese A, Paneth-Pollak R, Dorsinville MS, Ngai S, Reilly KH.

Multisystem inflammatory syndrome in children and SARS-CoV-2: A scoping review

Panigrahy N, Policarpio J, Ramanathan R.

[Covid-19, september 2020: fall storm warning]

Agut H.

Acute Kidney Injury in Multisystem Inflammatory Syndrome in Children (MIS-C): a Case Report

Lee M, Hilado M, Sotelo S, Opas LM, Im DD.

The perfect storm: A Case of COVID-19 infection in an adolescent patient with EVALI

Bozkanat KM, Rao D, Lieu TJ, Rivera-Sanchez YM.

Relationship between children physical activity, inflammatory mediators and lymphocyte activation: possible impact of social isolation (COVID-19)

Merlin M, de Oliveira HH, Passos MEP, Momesso CM, Dos Santos de Oliveira LC, Santana JE, Levada-Pires AC, Hatanaka E, Massao-Hirabara S, Guaré R, Cury-Boaventura MF, Pithon-Curi TC, Gorjão R.

The DHODH Inhibitor PTC299 Arrests SARS-CoV-2 Replication and Suppresses Induction of Inflammatory Cytokines

Luban J, Sattler R, Mühlberger E, Graci JD, Cao L, Weetall M, Trotta C, Colacino JM, Bavari S, Strambio-De-Castillia C, Suder EL, Wang Y, Soloveva V, Cintron-Lue K, Naryshkin NA, Pykett M, Welch EM, O'Keefe K, Kong R, Goodwin E, Jacobson A, Paessler S, Peltz S.

Letter to the Editor - in response to: Cardiac injury prediction and lymphocyte immunity and inflammation analysis in hospitalized patients with coronavirus disease 2019 (COVID-19)

Tan A, Jones DM, Ahmad M.

Post COVID Inflammation Syndrome: Different Manifestations Caused by the Virus

Chandrashekara S, Jaladhar P, Paramshetti S, Ramachandran V, Nizar SF, Kori D.

An inter-correlated cytokine network identified at the center of cytokine storm predicted COVID-19 prognosis

Liu Y, Chen D, Hou J, Li H, Cao D, Guo M, Ling Y, Gao M, Zhou Y, Wan Y, Zhu Z.

Inhaled route and anti-inflammatory action of ivermectin: Do they hold promise in fighting against COVID-19?

Mittal N, Mittal R.

A bioinformatic approach to investigating cytokine genes and their receptor variants in relation to COVID-19 progression

Karakas Celik S, Cakmak Genc G, Dursun A.

MEK inhibitors reduce cellular expression of ACE2, pERK, pRb while stimulating NK-mediated cytotoxicity and attenuating inflammatory cytokines relevant to SARS-CoV-2 infection

Zhou L, Huntington K, Zhang S, Carlsen L, So EY, Parker C, Sahin I, Safran H, Kamle S, Lee CM, Geun Lee C, A Elias J, S Campbell K, T Naik M, J Atwood W, Youssef E, A Pachter J, Navaraj A, A Seyhan A, Liang O, S El-Deiry W.

Increased inflammatory markers correlate with liver damage and predict severe COVID-19: a systematic review and meta-analysis

Amiri-Dashatan N, Koushki M, Ghorbani F, Naderi N.

Same pollution sources for climate change might be hyperactivating the NLRP3 inflammasome and exacerbating neuroinflammation and SARS mortality

Macias-Verde D, Lara PC, Burgos-Burgos J.

Severe manifestations of SARS-CoV-2 in children and adolescents: from COVID-19 pneumonia to multisystem inflammatory syndrome: a multicentre study in pediatric intensive care units in Spain

García-Salido A, de Carlos Vicente JC, Belda Hofheinz S, Balcells Ramírez J, Slöcker Barrio M, Leóz Gordillo I, Hernández Yuste A, Guitart Pardellans C, Cuervas-Mons Tejedor M, Huidobro Labarga B, Vázquez Martínez JL, Gutiérrez Jimeno M, Oulego-Erróz I, Trastoy Quintela J, Medina Monzón C, Medina Ramos L, Holanda Peña MS, Gil-Antón J, Sorribes Ortí C, Flores González JC, Hernández Palomo RM, Sánchez Ganfornina I, Fernández Romero E, García-Besteiro M, López-Herce Cid J, Gonzá

Cytokine storm of a different flavor: the different cytokine signature of SARS-CoV2 the cause of COVID-19 from the original SARS outbreak

Griffin DO, Jensen A, Khan M, Chin J, Chin K, Saad J, Parnell R, Awwad C, Patel D.

Multisystem Inflammatory Syndrome in Children during the COVID-19 Pandemic: A Case Report on Managing the Hyperinflammation

Cirks BT, Geracht JC, Jones OY, May JW, Mikita CP, Rajnik M, Helfrich AM.

Management of Patients With Inflammatory Rheumatic Diseases: Telemedicine and Rheumatologists Challenged in the Era of COVID-19

Foti R, Amato G, Foti R, Visalli E.

Multisystem Inflammatory Syndrome in Children, the Real Disease of COVID-19 in Pediatrics - A Multicenter Case Series From Al-Ahsa, Saudi Arabia

Almoosa ZA, Al Ameer HH, AlKadhem SM, Busaleh F, AlMuhanna FA, Kattih O.

Electrical storm in a patient with COVID-19 treated with hydroxychloroquine: A case report

Vetta F, Marinaccio L, Vetta G, Marchese D.

Use of Cannabinoids to Treat Acute Respiratory Distress Syndrome and Cytokine Storm Associated with Coronavirus Disease-2019

Nagarkatti P, Miranda K, Nagarkatti M.

Longitudinal proteomic profiling reveals increased early inflammation and sustained apoptosis proteins in severe COVID-19

Haljasmägi L, Salumets A, Rumm AP, Jürgenson M, Krassohhina E, Remm A, Sein H, Kareinen L, Vapalahti O, Sironen T, Peterson H, Milani L, Tamm A, Hayday A, Kisand K, Peterson P.

A 23-Year-Old Man With Multisystem Inflammatory Syndrome After Mild COVID-19

Razavi AC, Chang JL, Sutherland A, Niyogi A, Ménard GE.

Riders on the Storm: Did COVID-19 Change Children's Emotional and Behavioral Profile? A Brief Exploratory Survey

Zaccaria V, Aricò M, Vigliante M, Prono F, Scarselli V, Ardizzone I, Romani M.

Covid-19 and leptospirosis: Cytokine storm and the use of steroids

Ittyachen AM.

The Hyper-Inflammatory Response in Adults with Severe COVID-19 Pneumonia Differs from the Cytokine Storm of Hemophagocytic Syndrome

Brikman S, Bieber A, Dori G.

Novel gene-specific translation mechanism of dysregulated, chronic inflammation reveals promising, multifaceted COVID-19 therapeutics

Wang L, Muneer A, Xie L, Zhang F, Wu B, Mei L, Lenarcic EM, Feng EH, Song J, Xiong Y, Yu X, Wang C, Gheorghe C, Torralba K, Cook JG, Wan YY, Moorman NJ, Song H, Jin J, Chen X.

Psychological challenges for Inflammatory Bowel Disease patients during COVID-19 pandemic

Borghi L, Poli S, Furfaro F, Allocca M, Vegni EAM.

Biomimetic Nanoparticles Potentiate the Anti-Inflammatory Properties of Dexamethasone and Reduce the Cytokine Storm Syndrome: An Additional Weapon against COVID-19?

Molinaro R, Pasto A, Taraballi F, Giordano F, Azzi JA, Tasciotti E, Corbo C.

In the Eye of the Storm: The Role of the Pharmacist in Medication Safety during the COVID-19 Pandemic at an Urban Teaching Hospital

Kanaan AO, Sullivan KM, Seed SM, Cookson NA, Spooner LM, Abraham GM.

Fostering Mesenchymal Stem Cell Therapy to Halt Cytokine Storm in COVID-19

Jeyaraman M, John A, Koshy S, Ranjan R, TalagavadiChannaiahAnudeep, Jain R, Swati K, Jha NK, Sharma A, Kesari KK, Prakash A, Nand P, Jha SK, Reddy PH.

IMPACT OF THE COVID-19 PANDEMIC ON TREATMENT ADHERENCE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: EXPERIENCE OF A TERTIARY HOSPITAL IN CHILE

Quera R, Simian D, Flores L, Ibáñez P, Figueroa C.

Physician practice patterns on holding inflammatory bowel disease medications due to COVID-19 in the SECURE-IBD registry

Agrawal M, Brenner EJ, Zhang X, Colombel JF, Kappelman MD, Ungaro RC.

Estimating the release of inflammatory factors and use of glucocorticoid therapy for COVID-19 patients with comorbidities

Han D, Peng C, Meng R, Yao J, Zhou Q, Xiao Y, Ma H.

Recommendations for the initial management of multisystem inflammatory syndrome temporally related to COVID-19, in children and adolescents

Kohn-Loncarica G, Fustiñana A, Díaz-Rubio F, Jaramillo-Bustamante JC, González-Dambrauskas S, Vásquez-Hoyos P, Fernández-Sarmiento J, González G, Mansur A, Ponce J, Jabornisky R.

Thromboinflammation in COVID-19: Can α(2) -Macroglobulin Help to Control the Fire?

Seitz R, Gürtler L, Schramm W.

Liver Injury in Hospitalized Patients with COVID-19 Correlates with Hyper Inflammatory Response and Elevated IL-6

Da BL, Kushner T, El Halabi M, Paka P, Khalid M, Uberoi A, Lee BT, Perumalswami PV, Rutledge SM, Schiano TD, Friedman S, Saberi B.

Impact of COVID-19 on a cohort of patients with inflammatory bowel disease at a specialised centre in Chile

Quera R, Pizarro G, Simian D, Ibáñez P, Lubascher J, Kronberg U, Flores L, Figueroa C.

Comparison of clinical, para-clinical and laboratory findings in survived and deceased patients with COVID-19: diagnostic role of inflammatory indications in determining the severity of illness

Rokni M, Ahmadikia K, Asghari S, Mashaei S, Hassanali F.

Peripheral blood inflammatory markers in predicting prognosis in patients with COVID-19. Some differences with influenza A

Zhao Y, Yu C, Ni W, Shen H, Qiu M, Zhao Y.

Case Series of Chronic Inflammatory Rheumatic Disease Patients Infected by Coronavirus Disease 2019 (COVID-19)

Tiendrébéogo WJS, Kaboré F, Diendéré EA, Ouedraogo DD.

Can COVID-19 trigger de novo inflammatory bowel disease?

Taxonera C, Fisac J, Alba C.

Magnesium and inflammation: Advances and perspectives

Maier JA, Castiglioni S, Locatelli L, Zocchi M, Mazur A.

Obesity, Diabetes, Non-alcoholic Fatty Liver Disease and Metabolic Dysfunction Associated Fatty Liver Disease are Proinflammatory Hypercoagulable States associated with Severe Disease and Thrombosis in Covid-19

Ji D, Zhang M, Qin E, Zhang L, Xu J, Wang Y, Cheng G, Wang F, Lau G.

Severe COVID-19, multisystem inflammatory syndrome in children, and Kawasaki disease: immunological mechanisms, clinical manifestations and management

Kabeerdoss J, Pilania RK, Karkhele R, Kumar TS, Danda D, Singh S.

From dermatological conditions to COVID-19: reasoning for anticoagulation, suppression of inflammation, and hyperbaric oxygen therapy

Criado PR, Miot HA, Pincelli TPH, Fabro AT.

How do surgeons weather the storm of COVID-19 pandemic?

Voon K, Premnath N.

Response to: 'Correspondence on 'Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort' by Pouletty et al ' by Ventura et al

Chommeloux J, Pouletty M, Ouldali N, Kerneis M, Mathian A, Mestiri R, Rohmer J, Hekimian G, Melki I; Great Paris Region (GPR) Kawa-COVID-19 consortium.

Association of elevated inflammatory markers and severe COVID-19: A meta-analysis

Ji P, Zhu J, Zhong Z, Li H, Pang J, Li B, Zhang J.

Case Report: Pediatric Patient with COVID-19 and Multisystem Inflammatory Syndrome in Children

Burger MW, Moore MA, Wilburn JM.

The same storm but not the same boat: Effects of COVID-19 stay-at-home order on mental health in individuals with overweight

Lofrano-Prado MC, do Prado WL, Botero JP, Cardel ML, Farah BQ, Oliveira MD, Cucato GG, Correia MA, Ritti-Dias RM.

Vascular neutrophilic inflammation and immunothrombosis distinguish severe COVID-19 from influenza pneumonia

Nicolai L, Leunig A, Brambs S, Kaiser R, Joppich M, Hoffknecht M, Gold C, Engel A, Polewka V, Muenchhoff M, Hellmuth JC, Ruhle A, Ledderose S, Weinberger T, Schulz H, Scherer C, Rudelius M, Zoller M, Keppler OT, Zwißler B, von Bergwelt-Baildon M, Kääb S, Zimmer R, Bülow RD, von Stillfried S, Boor P, Massberg S, Pekayvaz K, Stark K.

Analysis of vitamin D level among asymptomatic and critically ill COVID-19 patients and its correlation with inflammatory markers

Jain A, Chaurasia R, Sengar NS, Singh M, Mahor S, Narain S.

COVID-19 inflammation results in urine cytokine elevation and causes COVID-19 associated cystitis (CAC)

Lamb LE, Dhar N, Timar R, Wills M, Dhar S, Chancellor MB.

Atypical monocytes in COVID-19: Lighting the fire of cytokine storm?

Pence BD.

Elevated markers of thrombo-inflammatory activation predict outcome in patients with cardiovascular comorbidities and COVID-19 disease: insights from the LEOSS registry

Cremer S, Jakob C, Berkowitsch A, Borgmann S, Pilgram L, Tometten L, Classen A, Wille K, Weidlich S, Gruener B, Dimmeler S, Massberg S, Rieg S, Zeiher AM; LEOSS study group.

A digital protein microarray for COVID-19 cytokine storm monitoring

Song Y, Ye Y, Su SH, Stephens A, Cai T, Chung MT, Han MK, Newstead MW, Yessayan L, Frame D, Humes HD, Singer BH, Kurabayashi K.

Risk and outcomes of coronavirus disease (COVID-19) in patients with inflammatory bowel disease: a systematic review and meta-analysis

Singh AK, Jena A, Kumar-M P, Sharma V, Sebastian S.

Cardiac injury is associated with inflammation in geriatric COVID-19 patients

Yan X, Wang S, Ma P, Yang B, Si D, Liu G, Liu L, Ding M, Yang W, Li J, Sun H, Yang P.

Does COVID-19 cause an increased risk of hospitalization or death in patients with inflammatory rheumatic diseases treated with biological DMARDs or targeted synthetic DMARDs?

Lwin M, Holroyd C, Wallis D, Davidson B, Goulston L, de Graaf H, Edwards CJ.

Clinical course of COVID-19 infection in inflammatory rheumatological patients: a monocentric Belgian experience

Pistone A, Tant L, Soyfoo MS.

Systematic Examination of Antigen-Specific Recall T Cell Responses to SARS-CoV-2 versus Influenza Virus Reveals a Distinct Inflammatory Profile

Law JC, Koh WH, Budylowski P, Lin J, Yue F, Abe KT, Rathod B, Girard M, Li Z, Rini JM, Mubareka S, McGeer A, Chan AK, Gingras AC, Watts TH, A Ostrowski M.

Epicardial adipose tissue, inflammatory biomarkers and COVID-19: Is there a possible relationship?

Abrishami A, Eslami V, Baharvand Z, Khalili N, Saghamanesh S, Zarei E, Sanei-Taheri M.

Heart Rate Variability as a Possible Predictive Marker for Acute Inflammatory Response in COVID-19 Patients

Hasty F, García G, Dávila CH, Wittels SH, Hendricks S, Chong S.

Multisystem inflammatory syndrome in adult COVID-19 patients

Parker A, Louw EH, Lalla U, Koegelenberg CFN, Allwood BW, Rabie H, Sibeko SI, Taljaard JJ, Lahri S.

COVID-19 cytokine storm: what is in a name?

Nigrovic PA.

An enlightening role for cytokine storm in coronavirus infection

Zhao Z, Wei Y, Tao C.

The Pivotal Role of Adipocyte-Na K peptide in Reversing Systemic Inflammation in Obesity and COVID-19 in the Development of Heart Failure

Xie ZJ, Novograd J, Itzkowitz Y, Sher A, Buchen YD, Sodhi K, Abraham NG, Shapiro JI.

Characteristics of pediatric multi-system inflammatory syndrome (PMIS) associated with COVID-19: a meta-analysis and insights into pathogenesis

Zou H, Lu J, Liu J, Wong JH, Cheng S, Li Q, Shen Y, Li C, Jia X.

Cytokine Storm May Not Be the Chief Culprit for the Deterioration of COVID-19

Gao Y, Wang C, Kang K, Peng Y, Luo Y, Liu H, Yang W, Zhao M, Yu K.

Tocilizumab in hospitalized patients with COVID-19: Clinical outcomes, inflammatory marker kinetics, and safety

Hill JA, Menon MP, Dhanireddy S, Wurfel MM, Green M, Jain R, Chan JD, Huang J, Bethune D, Turtle C, Johnston C, Xie H, Leisenring WM, Nina Kim H, Cheng GS.

CD127 imprints functional heterogeneity to diversify monocyte responses in human inflammatory diseases

Zhang B, Zhang Y, Xiong L, Li Y, Zhang Y, Zhao J, Jiang H, Li C, Liu Y, Liu X, Liu H, Ping YF, Zhang QC, Zhang Z, Bian XW, Zhao Y, Hu X.

Covid-19 cytokine storm in pulmonary tissue: anatomopathological and immunohistochemical findings

Miggiolaro AFRDS, Motta Junior JDS, de Paula CBV, Nagashima S, Malaquias MAS, Carstens LB, Novais AM, Baena CP, de Noronha L.

[Proinflammatory cytokines and cardio-vascular risk: From myocardial infarction tocytokine storm of COVID-19]

Miossec P.

Similarities and differences between the 'cytokine storms' in acute dengue and COVID-19

Dayarathna S, Jeewandara C, Gomes L, Somathilaka G, Jayathilaka D, Vimalachandran V, Wijewickrama A, Narangoda E, Idampitiya D, Ogg GS, Malavige GN.

Broncho-alveolar inflammation in COVID-19 patients: a correlation with clinical outcome

Pandolfi L, Fossali T, Frangipane V, Bozzini S, Morosini M, D'Amato M, Lettieri S, Urtis M, Di Toro A, Saracino L, Percivalle E, Tomaselli S, Cavagna L, Cova E, Mojoli F, Bergomi P, Ottolina D, Lilleri D, Corsico AG, Arbustini E, Colombo R, Meloni F.

Early use of non-steroidal anti-inflammatory drugs in COVID-19 might reverse pathogenesis, prevent complications and improve clinical outcomes

Kelleni MT.

Management of severe hyperinflammation in the COVID-19 era: the role of the rheumatologist

Papadopoulou C, Al Obaidi M, Moraitis E, Compeyrot-Lacassagne S, Eleftheriou D, Brogan P.

Early plasma IL-37 responses accompanied with low inflammatory cytokines correlate with benign clinical outcomes during SARS-CoV-2 infection

Li A, Ling Y, Song Z, Cheng X, Ding L, Jiang R, Fu W, Liu Y, Hu H, Yuan S, Chen J, Zhu C, Fan J, Wang J, Jin Y, Zhang M, Zhu L, Sun P, Zhang L, Qin R, Zhang W, Qiu C, Shen Y, Zhang L, Shi Z, Zhao C, Zhu T, Lu H, Zhang X, Xu J.

Management of Patients with Inflammatory Diseases during the COVID-19 Pandemic

Apostolou T, Koutroubakis IE, Manolakopoulos S, Mantzaris G, Rigopoulos D, Triantafyllou K, Vassilopoulos D.

Practical Issues in Managing Systemic Inflammatory Disorders During the COVID-19 Pandemic

Dimitroulas T, Bertsias G.

Coagulopathy as a Prodrome of Cytokine Storm in COVID-19-Infected Patients

Guo H, Sheng Y, Li W, Li F, Xie Z, Li J, Zhu Y, Geng J, Liu G, Wang L, Li J, Wang F.

Tocilizumab: The Key to Stop Coronavirus Disease 2019 (COVID-19)-Induced Cytokine Release Syndrome (CRS)?

Liu D, Zhang T, Wang Y, Xia L.

miR-1207-5p Can Contribute to Dysregulation of Inflammatory Response in COVID-19 via Targeting SARS-CoV-2 RNA

Bertolazzi G, Cipollina C, Benos PV, Tumminello M, Coronnello C.

A Rare Presentation of Multi-System Inflammatory Disease in Children Associated With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Makvandi S, Alibrahim O, Abdul-Aziz R, Abdul-Fattah Sallam M, McGreevy M.

[SARS-CoV-2 infection in a patient treated by hydroxychloroquine and anti TNF α for Inflammatory Rheumatic Disease]

Malek SA, Bouchti IE.

Prognostic Value of Pro-Inflammatory Neutrophils and C-Reactive Protein in Cancer Patient With Coronavirus Disease 2019: A Multi-Center, Retrospective Study

Zhang B, Yu Y, Hubert SM, Zhang Y, Lu J, Liu S, Xie F, Zhao L, Lei X, Deng W, Chen J, Li Y.

Efficacy and safety of early treatment with sarilumab in hospitalised adults with COVID-19 presenting cytokine release syndrome (SARICOR STUDY): protocol of a phase II, open-label, randomised, multicentre, controlled clinical trial

León López R, Fernández SC, Limia Pérez L, Romero Palacios A, Fernández-Roldán MC, Aguilar Alonso E, Pérez Camacho I, Rodriguez-Baño J, Merchante N, Olalla J, Esteban-Moreno MÁ, Santos M, Luque-Pineda A, Torre-Cisneros J.

Multisystem inflammatory syndrome in children rose and fell with the first wave of the COVID-19 pandemic in France

Carbajal R, Lorrot M, Levy Y, Grimprel E, Lecarpentier T, Heritier S, Faivre J, Schnuriger A, Parisot P, Blondiaux E, Loschi S, Rivière S, Guilbert J, Romain AS, Leger PL, Guedj R.

CB2 receptor-selective agonists as candidates for targeting infection, inflammation, and immunity in SARS-CoV-2 infections

Nagoor Meeran MF, Sharma C, Goyal SN, Kumar S, Ojha S.

Efficacy of therapeutic plasma exchange in the treatment of penn class 3 and 4 cytokine release syndrome complicating COVID-19

Gluck WL, Callahan SP, Brevetta RA, Stenbit AE, Smith WM, Martin JC, Blenda AV, Arce S, Edenfield WJ.

Effectiveness and safety of intravenous tocilizumab to treat COVID-19-associated hyperinflammatory syndrome: Covizumab-6 observational cohort

Corominas H, Castellví I, Pomar V, Antonijoan R, Mur I, Matas L, Gich I, de Benito N, Laiz A, Castillo D, Villamarin L, Filella D, Millán AM, Quijada MÁ, Puig M, Casademont J, Domingo P.

The key role of Warburg effect in SARS-CoV-2 replication and associated inflammatory response

Icard P, Lincet H, Wu Z, Coquerel A, Forgez P, Alifano M, Fournel L.

Venous thrombosis, thromboembolism and biomarkers of inflammation and coagulation in COVID-19

Thondapu V, Montes D, Rosovsky R, Dua A, McDermott S, Lu MT, Ghoshhajra B, Hoffmann U, Gerhard-Herman MD, Hedgire S.

Treating exuberant, non-resolving inflammation in the lung; implications for acute respiratory distress syndrome and COVID-19

Gilroy DW, De Maeyer RPH, Tepper M, O'Brien A, Uddin M, Chen J, Goldstein DR, Akbar AN.

Distinct inflammatory profiles distinguish COVID-19 from influenza with limited contributions from cytokine storm

Mudd PA, Crawford JC, Turner JS, Souquette A, Reynolds D, Bender D, Bosanquet JP, Anand NJ, Striker DA, Martin RS, Boon ACM, House SL, Remy KE, Hotchkiss RS, Presti RM, O'Halloran JA, Powderly WG, Thomas PG, Ellebedy AH.

CCR5 Inhibition in Critical COVID-19 Patients Decreases Inflammatory Cytokines, Increases CD8 T-Cells, and Decreases SARS-CoV2 RNA in Plasma by Day 14

Patterson BK, Seethamraju H, Dhody K, Corley MJ, Kazempour K, Lalezari J, Pang APS, Sugai C, Mahyari E, Francisco EB, Pise A, Rodrigues H, Wu HL, Webb GM, Park BS, Kelly S, Pourhassan N, Lelic A, Kdouh L, Herrera M, Hall E, Bimber BN, Plassmeyer M, Gupta R, Alpan O, O'Halloran JA, Mudd PA, Akalin E, Ndhlovu LC, Sacha JB.

Multisystem inflammatory syndrome in children (MIS-C) during SARS-CoV-2 pandemic in Brazil: a multicenter, prospective cohort study

Lima-Setta F, Magalhães-Barbosa MC, Rodrigues-Santos G, Figueiredo EADN, Jacques ML, Zeitel RS, Sapolnik R, Borges CTDS, Lanziotti VS, Castro REV, Bellinat APN, Silva TPD, Oliveira FRC, Reis BCSD, Castro NAASR, Macedo JHGC, Scarlato ACCP, Riveiro PM, Mota ICFD, Lorenzo VB, Lucena NML, Azevedo ZMA, Cunha AJLA, Prata-Barbosa A; Brazilian Research Network in Pediatric Intensive Care (BRnet-PIC).

Non-steroidal anti-inflammatory drugs and susceptibility to COVID-19

Chandan JS, Zemedikun DT, Thayakaran R, Byne N, Dhalla S, Acosta-Mena D, Gokhale KM, Thomas T, Sainsbury C, Subramanian A, Cooper J, Anand A, Okoth KO, Wang J, Adderley NJ, Taverner T, Denniston AK, Lord J, Thomas GN, Buckley CD, Raza K, Bhala N, Nirantharakumar K, Haroon S.

COVID-19 susceptibility in pregnancy: Immune/inflammatory considerations, the role of placental ACE-2 and research considerations

Malinowski AK, Noureldin A, Othman M.

COVID-19 and Comorbidities: is Inflammation the Underlying Condition in Children? A narrative Review

Pinna G, Sanfilippo L, Bassareo PP, Fanos V, Marcialis MA.

Anti-Inflammatory Effects of Amantadine and Memantine: Possible Therapeutics for the Treatment of Covid-19?

Jiménez-Jiménez FJ, Alonso-Navarro H, García-Martín E, Agúndez JAG.

Multisystem inflammatory syndrome with refractory cardiogenic shock due to acute myocarditis and mononeuritis multiplex after SARS-CoV-2 infection in an adult

Othenin-Girard A, Regamey J, Lamoth F, Horisberger A, Glampedakis E, Epiney JB, Kuntzer T, de Leval L, Carballares M, Hurni CA, Rusca M, Pantet O, Di Bernardo S, Oddo M, Comte D, Piquilloud L.

Fatal SARS-CoV-2 Inflammatory Syndrome and Myocarditis in an Adolescent: A Case Report

Beaudry JT, Dietrick B, Lammert DB, Constas A, McCaw J, Hammond J, Buendia M, Stein JE, Pekosz A, Schuette J, Mostafa HH, Hooper JE, Bernier M, Agwu A, Feldman LS.

From angiotensin-converting enzyme 2 disruption to thromboinflammatory microvascular disease: A paradigm drawn from COVID-19

Vinci R, Pedicino D, Andreotti F, Russo G, D'Aiello A, De Cristofaro R, Crea F, Liuzzo G.

Russelioside B; A Pregnane Glycoside for Treatment of Gastric Ulcer via Modulation of Heat Shock Protein-70 and Vascular Endothelial Growth Factor

El-Shiekh RA, Salama A, Al-Mokaddem AK, Bader A, Abdel-Sattar EA.

Immunological assessment of pediatric multisystem inflammatory syndrome related to COVID-19

Grazioli S, Tavaglione F, Torriani G, Wagner N, Rohr M, L'Huillier AG, Leclercq C, Perrin A, Bordessoule A, Beghetti M, Pachlopnik J, Vavassori S, Perreau M, Eberhardt C, Didierlaurent A, Kaiser L, Eckerle I, Roux-Lombard P, Blanchard-Rohner G.

New onset diabetes with diabetic ketoacidosis in a child with multisystem inflammatory syndrome due to COVID-19

Naguib MN, Raymond JK, Vidmar AP.

Lessons From the First Wave of the Pandemic: Skin Features of COVID-19 can be Divided Into Inflammatory and Vascular Patterns

Naderi-Azad S, Vender R.

Mesenchymal stem cells as living anti-inflammatory therapy for COVID-19 related acute respiratory distress syndrome

Lin F, Ichim TE, Pingle S, Jones LD, Kesari S, Ashili S.

Correspondence on 'Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort'

Ruyssen-Witrand A, Soubrier M, Basch A, Truchetet ME, Seror R.

Response to 'Correspondence on 'Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort' by Ruyssen-Witrand et al

Ciurea A, Finckh A.

Hemoperfusion as a Potential Treatment for Critically Ill COVID-19 Patients with Cytokine Storm

Shadvar K, Tagizadiyeh A, Gamari AA, Soleimanpour H, Mahmoodpoor A.

Expressive writing to combat distress associated with the COVID-19 pandemic in people with inflammatory bowel disease (WriteForIBD): A trial protocol

Mikocka-Walus A, Olive L, Skvarc D, Beswick L, Massuger W, Raven L, Emerson C, Evans S.

Multisystem Inflammatory Syndrome in Children Related to COVID-19: the First Case in Korea

Kim H, Shim JY, Ko JH, Yang A, Shim JW, Kim DS, Jung HL, Kwak JH, Sol IS.

Proinflammatory IgG Fc structures in patients with severe COVID-19

Chakraborty S, Gonzalez J, Edwards K, Mallajosyula V, Buzzanco AS, Sherwood R, Buffone C, Kathale N, Providenza S, Xie MM, Andrews JR, Blish CA, Singh U, Dugan H, Wilson PC, Pham TD, Boyd SD, Nadeau KC, Pinsky BA, Zhang S, Memoli MJ, Taubenberger JK, Morales T, Schapiro JM, Tan GS, Jagannathan P, Wang TT.

Clinical characteristics of 10 children with a pediatric inflammatory multisystem syndrome associated with COVID-19 in Iran

Shahbaznejad L, Navaeifar MR, Abbaskhanian A, Hosseinzadeh F, Rahimzadeh G, Rezai MS.

Acute Cardiovascular Manifestations in 286 Children with Multisystem Inflammatory Syndrome Associated with COVID-19 Infection in Europe

Valverde I, Singh Y, Sanchez-de-Toledo J, Theocharis P, Chikermane A, Di Filippo S, Kucinska B, Mannarino S, Tamariz-Martel A, Gutierrez-Larraya F, Soda G, Vandekerckhove K, Gonzalez Barlatey F, McMahon CJ, Marcora SA, Pace Napoleone C, Duong P, Tuo G, Deri A, Nepali G, Ilina M, Ciliberti P, Miller O; on behalf the AEPC COVID-19 rapid response team.

Review of Cardiac Involvement in Multisystem Inflammatory Syndrome in Children

Alsaied T, Tremoulet AH, Burns JC, Saidi A, Dionne A, Lang SM, Newburger JW, de Ferranti S, Friedman KG.

Does use of propofol aggravate the inflammatory markers and cause propofol infusion syndrome (PRIS) in intubated cases of severe COVID-19 infections?

Sharma B.

The effect of tocilizumab on cytokine release syndrome in COVID-19 patients

de Cáceres C, Martínez R, Bachiller P, Marín L, García JM.

Inflammatory endotypes of CRSwNP and responses to COVID-19

Wang M, Wang C, Zhang L.

Inflammatory Biomarker Trends Predict Respiratory Decline in COVID-19 Patients

Mueller AA, Tamura T, Crowley CP, DeGrado JR, Haider H, Jezmir JL, Keras G, Penn EH, Massaro AF, Kim EY.

Cytokine storm induced new onset depression in patients with COVID-19. A new look into the association between depression and cytokines -two case reports

Alpert O, Begun L, Garren P, Solhkhah R.

A fatal course of multiple inflammatory syndrome in children coinfection with dengue. A case report from Indonesia

Somasetia DH, Malahayati TT, Andriyani FM, Setiabudi D, Nataprawira HM.

Inflammatory bowel disease amid the COVID-19 pandemic: impact, management strategies, and lessons learned

Gajendran M, Perisetti A, Aziz M, Raghavapuram S, Bansal P, Tharian B, Goyal H.

Application value of artificial liver support system in the treatment of cytokine storm in patients with COVID-19

Xia Q, Xu K, Yu L, Zhang H, Li L.

Multisystem Inflammatory Syndrome in Children

Tabaac S, Kothari P, Cassidy-Smith T.

Through the Storm: Automated Peritoneal Dialysis with Remote Patient Monitoring during COVID-19 Pandemic

Bunch A, Ardila F, Castaño R, Quiñonez S, Corzo L.

Altered intestinal ACE2 levels are associated with inflammation, severe disease and response to anti-cytokine therapy in IBD

Potdar AA, Dube S, Naito T, Li K, Botwin G, Haritunians T, Li D, Casero D, Yang S, Bilsborough J, Perrigoue JG, Denson LA, Daly M, Targan SR, Fleshner P, Braun J, Kugathasan S, Stappenbeck TS, McGovern DPB.

Role of Systemic and Nasal Glucocorticoid Treatment in the Regulation of the Inflammatory Response in Patients with SARS-Cov-2 Infection

Cárdenas G, Torres-García D, Cervantes-Torres J, Rosales-Mendoza S, Fleury A, Fragoso G, Laclette JP, Sciutto E.

Substance P, proinflammatory cytokines, transient receptor potential vanilloid subtype 1 and COVID-19: A working hypothesis

Aguirre-Siancas EE, Colona-Vallejos E, Ruiz-Ramirez E, Becerra-Bravo M, Alzamora-Gonzales L.

Shelter from the cytokine storm: pitfalls and prospects in the development of SARS-CoV-2 vaccines for an elderly population

Ciabattini A, Garagnani P, Santoro F, Rappuoli R, Franceschi C, Medaglini D.

Age-severity matched cytokine profiling reveals specific signatures in Covid-19 patients

Angioni R, Sánchez-Rodríguez R, Munari F, Bertoldi N, Arcidiacono D, Cavinato S, Marturano D, Zaramella A, Realdon S, Cattelan A, Viola A, Molon B.

Influence of COVID-19 pandemic on decisions for the management of people with inflammatory rheumatic and musculoskeletal diseases: a survey among EULAR countries

Dejaco C, Alunno A, Bijlsma JW, Boonen A, Combe B, Finckh A, Machado PM, Padjen I, Sivera F, Stamm TA, Buttgereit F.

Shufeng Jiedu, a promising herbal therapy for moderate COVID-19:Antiviral and anti-inflammatory properties, pathways of bioactive compounds, and a clinical real-world pragmatic study

Xia L, Shi Y, Su J, Friedemann T, Tao Z, Lu Y, Ling Y, Lv Y, Zhao R, Geng Z, Cui X, Lu H, Schröder S.

Is COVID-19 a Perfect Storm for Parkinson's Disease?

Brundin P, Nath A, Beckham JD.

Clinical, inflammatory, and immune differences between COVID-19 patients with and without cancer: A protocol for systematic review and meta-analysis

Yu Z, Wang P, Chen B, Zhang Z, Jiang J, Zhuang Y.

ReumaCoV Brasil Registry: a Brazilian cohort of Patients with Immuno-mediated Chronic Inflammatory Diseases Infected by SARS-CoV-2

Marques C, Kakehasi AM, Gomides APM, Paiva EDS, Dos Reis Neto ET, Pileggi GCS, Provenza JR, da Mota LMH, Xavier RM, Ferreira GA, Pinheiro MM.

Enhanced expression of ACE2 in psoriatic skin and its upregulation in keratinocytes by interferon-gamma: Implication of inflammatory milieu in skin tropism of SARS-CoV-2

Tembhre MK, Parihar AS, Sharma VK, Imran S, Bhari N, Lakshmy R, Bhalla A.

Coronaviruses: Innate Immunity, Inflammasome Activation, Inflammatory Cell Death, and Cytokines

Lee S, Channappanavar R, Kanneganti TD.

Molecular screening of antimalarial, antiviral, anti-inflammatory and HIV protease inhibitors against spike glycoprotein of coronavirus

Prashantha CN, Gouthami K, Lavanya L, Bhavanam S, Jakhar A, Shakthiraju RG, Suraj V, Sahana KV, Sujana HS, Guruprasad NM, Ramachandra R.

COVID-19 in French patients with chronic inflammatory rheumatic diseases: clinical features, risk factors and treatment adherence

Costantino F, Bahier L, Tarancón LC, Leboime A, Vidal F, Bessalah L, Breban M, D'Agostino MA.

Platelets and COVID-19: Inflammation, Hyperactivation and Additional Questions

Koupenova M, Freedman JE.

SARS-CoV-2 and inflammatory responses: from mechanisms to the potential therapeutic use of intravenous immunoglobulin

Mascolo S, Carleo MA, Contieri M, Izzo S, Perna A, De Luca A, Esposito V.

Teleconsultation experience with the idiopathic inflammatory myopathies: a prospective observational cohort study during the COVID-19 pandemic

Naveen R, Sundaram TG, Agarwal V, Gupta L.

Covid-19 and the management of patients with inflammatory bowel disease: a practical decalogue for the post-pandemic phase

Papa A, Papa V, Lopetuso LR, Gasbarrini A, Tursi A.

[Progress on role of cytokine storm in exacerbation of coronavirus disease 2019 (COVID-19): Review]

Liao J, Wen B, Deng X.

Shock and Myocardial Injury in Children With Multisystem Inflammatory Syndrome Associated With SARS-CoV-2 Infection: What We Know. Case Series and Review of the Literature

Caro-Patón GL, de Azagra-Garde AM, García-Salido A, Cabrero-Hernández M, Tamariz A, Nieto-Moro M.

A Case of Multisystem Inflammatory Syndrome in Children Mimicking Acute Appendicitis in a COVID-19 Pandemic Area

Jackson RJ, Chavarria HD, Hacking SM.

Classical Drug Digitoxin Inhibits Influenza Cytokine Storm, With Implications for Covid-19 Therapy

Pollard BS, BLANCOl JC, Pollard JR.

Patients with Inflammatory Bowel Disease Are Not at Increased Risk of COVID-19: A Large Multinational Cohort Study

Allocca M, Chaparro M, Gonzalez HA, Bosca-Watts MM, Palmela C, D'Amico F, Zacharopoulou E, Kopylov U, Ellul P, Bamias G, Ntelis V, Lahat A, Mantzaris GJ, Papaconstantinou I, Katsanos K, Uspenskaya Y, Christodoulou D, Ben Horin S, Peyrin-Biroulet L, Torres J, Sebastian S, Gisbert JP, Danese S, Fiorino G.

COVID-19 and Parkinson's Disease: Shared Inflammatory Pathways Under Oxidative Stress

Chaudhry ZL, Klenja D, Janjua N, Cami-Kobeci G, Ahmed BY.

COVID-19: Cytokine storm modulation/blockade with oral polyvalent immunoglobulins (PVIG, KMP01D): A potential and safe therapeutic agent (Primum nil nocere)

Sly LM, Braun P, Woodcock BG.

COVID-19 cytokines and the hyperactive immune response: Synergism of TNF-α and IFN-γ in triggering inflammation, tissue damage, and death

Karki R, Sharma BR, Tuladhar S, Williams EP, Zalduondo L, Samir P, Zheng M, Sundaram B, Banoth B, Malireddi RKS, Schreiner P, Neale G, Vogel P, Webby R, Jonsson CB, Kanneganti TD.

Hypoxia: A key feature of COVID-19 launching activation of HIF-1 and cytokine storm

Jahani M, Dokaneheifard S, Mansouri K.

Impact of sandstorm and carnival celebrations on SARS-CoV-2 spreading in Tenerife and Gran Canaria (Canary Islands, Spain)

Tomaino L, Pinilla J, Rodríguez-Mireles S, González López-Valcárcel B, Barber-Pérez P, Sierra A, La Vecchia C, Serra-Majem L.

Eosinophilic pulmonary vasculitis as a manifestation of the hyperinflammatory phase of COVID-19

Luecke E, Jeron A, Kroeger A, Bruder D, Stegemann-Koniszewski S, Jechorek D, Borucki K, Reinhold D, Reinhold A, Foellner S, Walles T, Hachenberg T, Schreiber J.

Single-Cell Transcriptome Analysis Highlights a Role for Neutrophils and Inflammatory Macrophages in the Pathogenesis of Severe COVID-19

Shaath H, Vishnubalaji R, Elkord E, Alajez NM.

COVID-19, multisystem inflammatory syndrome in children, apoE4, and race

Goldstein MR, Poland GA, Graeber CW.

Treatment of Cytokine Storm in COVID-19 Patients With Immunomodulatory Therapy

Yessayan L, Szamosfalvi B, Napolitano L, Singer B, Kurabayashi K, Song Y, Westover A, Humes HD.

CIRPMC: An online model with simplified inflammatory signature to predict the occurrence of critical illness in patients with COVID-19

Gao Y, Chen L, Zeng S, Feng X, Chi J, Wang Y, Li H, Jiang T, Yu Y, Jiao X, Liu D, Feng X, Wang S, Yu R, Yuan Y, Xu S, Cai G, Xiong X, Chen P, Mo Q, Jin X, Wu Y, Ma D, Li C, Li SC, Gao Q.

Clinical Management of Il-6 Driven Cytokine Storm Related to COVID-19 in a Patient with Recent Spinal Cord Stimulator Implants: A Case Report

Papa A, Di Dato MT, Buonavolonta P, Saracco E, Salzano AM, Casale B.

Fecal calprotectin levels in COVID-19: Lessons from a systematic review on its use in inflammatory bowel disease during the pandemic

Jena A, Kumar-M P, Singh AK, Sharma V.

Multisystem inflammatory syndrome in children associated with novel coronavirus SARS-CoV-2: Presentations to a pediatric emergency department in Michigan

Sethuraman U, Kannikeswaran N, Ang J, Singer A, Miller J, Haddad R, Stankovic C.

[Proactive anti-inflammatory and anticoagulant therapy in the treatment of advanced stages of novel coronavirus infection (COVID-19). Case Series and Study Design: COLchicine versus ruxolitinib and secukinumab in open prospective randomIzed trial (COLORIT)]

Mareev VY, Orlova YA, Pavlikova EP, Akopyan ZA, Matskeplishvili ST, Plisyk AG, Seredenina EM, Potapenko AV, Malakhov PS, Samokhodskaya LM, Mershina ЕА, Sinitsyn VE, Asratyan DA, Zhdanova EA, Mareev YV, Begrambekova YL, Shatochina EA, Kamalov АА.

Inflammatory cytokines, T lymphocyte subsets, and ritonavir involved in liver injury of COVID-19 patients

Liao S, Zhan K, Gan L, Bai Y, Li J, Yuan G, Cai Y, Zhang A, He S, Mei Z.

Long-acting nanoparticulate DNase-1 for effective suppression of SARS-CoV-2-mediated neutrophil activities and cytokine storm

Lee YY, Park HH, Park W, Kim H, Jang JG, Hong KS, Lee JY, Seo HS, Na DH, Kim TH, Choy YB, Ahn JH, Lee W, Park CG.

The Role of Angiotensin Converting Enzyme 2 (ACE2) in Modulating Gut Microbiota, Intestinal Inflammation, and Coronavirus Infection

Penninger JM, Grant MB, Sung JJY.

Potential metabolic and inflammatory pathways between COVID-19 and new-onset diabetes

Sathish T, Tapp RJ, Cooper ME, Zimmet P.

Nano-curcumin therapy, a promising method in modulating inflammatory cytokines in COVID-19 patients

Valizadeh H, Abdolmohammadi-Vahid S, Danshina S, Ziya Gencer M, Ammari A, Sadeghi A, Roshangar L, Aslani S, Esmaeilzadeh A, Ghaebi M, Valizadeh S, Ahmadi M.

Correspondence to 'Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases'

Schulze-Koops H, Skapenko A, Krause A, Krueger K, Lorenz HM, Sewerin P, Specker C, Wagner UG, Voormann A, Mueller-Ladner U, Voll RE.

Response to: 'Correspondence on 'Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases'' by Schulze-Koops et al

Freites Nuñez DD, Leon L, Mucientes A, Rodriguez-Rodriguez L, Font Urgelles J, Madrid García A, Colomer JI, Jover JA, Fernandez-Gutierrez B, Abasolo L.

COVID-19 and Immune-Mediated Inflammatory Diseases: Why don't our patients get worse?

Martínez-Taboada VM, López-Hoyos M, Crespo J, Hernández JL.

Union is strength: antiviral and anti-inflammatory drugs for COVID-19

Naveja JJ, Madariaga-Mazón A, Flores-Murrieta F, Granados-Montiel J, Maradiaga-Ceceña M, Alaniz VD, Maldonado-Rodriguez M, García-Morales J, Senosiain-Peláez JP, Martínez-Mayorga K.

Maternal SARS-CoV-2 infection associated to systemic inflammatory response and pericardial effusion in the newborn: a Case-Report

Lima ARO, Cardoso CC, Bentim PRB, Voloch CM, Rossi ÁD, da Costa RMMSC, da Paz JAS, Agostinho RF, Figueiredo VRFS, Júnior JSS, de Almeida LGP, Gerber AL, Abuassi CA, Rodrigues NF, Tanuri A, Bozza PT, Bastos CS, de Vasconcelos ATR, Kruger SB, Vallim GGPCA, Nishihara RJ, Barroso SPC, Morrot A.

Inflammation and thrombosis in COVID-19 pathophysiology: Proteinase-activated and purinergic receptors as drivers and candidate therapeutic targets

Sriram K, Insel PA.

Pro- and Anti-Inflammatory Responses in Severe COVID-19-Induced Acute Respiratory Distress Syndrome-An Observational Pilot Study

Notz Q, Schmalzing M, Wedekink F, Schlesinger T, Gernert M, Herrmann J, Sorger L, Weismann D, Schmid B, Sitter M, Schlegel N, Kranke P, Wischhusen J, Meybohm P, Lotz C.

A "Window of Therapeutic Opportunity" for Anti-Cytokine Therapy in Patients With Coronavirus Disease 2019

De Stefano L, Bobbio-Pallavicini F, Manzo A, Montecucco C, Bugatti S.

ACE2, COVID-19 Infection, Inflammation, and Coagulopathy: Missing Pieces in the Puzzle

Abassi Z, Higazi AAR, Kinaneh S, Armaly Z, Skorecki K, Heyman SN.

Perfect storm: a rheumatologist's point of view on COVID-19 infection

Kobak S.

Cilastatin: a potential treatment strategy against COVID-19 that may decrease viral replication and protect from the cytokine storm

González-Nicolás MÁ, González-Guerrero C, Pérez-Fernández VA, Lázaro A.

Can Beta-2-Adrenergic Pathway Be a New Target to Combat SARS-CoV-2 Hyperinflammatory Syndrome?-Lessons Learned From Cancer

Barbieri A, Robinson N, Palma G, Maurea N, Desiderio V, Botti G.

Immune-Boosting, Antioxidant and Anti-inflammatory Food Supplements Targeting Pathogenesis of COVID-19

Mrityunjaya M, Pavithra V, Neelam R, Janhavi P, Halami PM, Ravindra PV.

Coagulopathy of Patients with COVID-19 is Associated with Infectious and Inflammatory Markers

Long X, Zhang Z, Zou W, Ling J, Li D, Jing L, Yu S, Zou X, Bian Y, Wu W, Li S, Fang M.

Cytokine Response in SARS-CoV-2 Infection in the Elderly

Sherwani S, Khan MWA.

Inflammatory Cytokine: IL-17A Signaling Pathway in Patients Present with COVID-19 and Current Treatment Strategy

Shibabaw T.

HIV/SARS-CoV-2 co-infection: T cell profile, cytokine dynamics and role of exhausted lymphocytes

Sharov KS.

Covid-19: Fat, Obesity, Inflammation, Ethnicity, and Sex Differences

Krams IA, Luoto S, Rantala MJ, Jõers P, Krama T.

Potential of natural astaxanthin in alleviating the risk of cytokine storm in COVID-19

Talukdar J, Bhadra B, Dattaroy T, Nagle V, Dasgupta S.

T-cell immunobiology and cytokine storm of COVID-19

Luo XH, Zhu Y, Mao J, Du RC.

Mechanisms and potential therapeutic targets of hyperinflammatory responses in SARS-CoV2

Chukwuma IF, Apeh VO, C OF.

Multisystem Inflammatory Syndrome in Children Temporally Related to COVID-19: A Case Report From Saudi Arabia

Al Ameer HH, AlKadhem SM, Busaleh F, AlKhwaitm S, Llaguno MBB.

The allergist/immunologist, the Janus gatekeeper of inflammation, COVID-19 and beyond

Bellanti JA, Settipane RA.

A case of COVID-19, with cytokine storm, treated by consecutive use of therapeutic plasma exchange followed by convalescent plasma transfusion: a case report

Ragab D, Salah Eldin H, Afify M, Soliman W, Badr MH.

Delayed acute myocarditis and COVID-19-related multisystem inflammatory syndrome

Nicol M, Cacoub L, Baudet M, Nahmani Y, Cacoub P, Cohen-Solal A, Henry P, Adle-Biassette H, Logeart D.

Can Cytokine Blocking Prevent Depression in COVID-19 Survivors?

Benedetti F, Mazza M, Cavalli G, Ciceri F, Dagna L, Rovere-Querini P.

Pediatric Inflammatory Multisystem Syndrome Temporally Associated with SARS-CoV-2: a New Challenge amid the Pandemic

Lawrensia S, Henrina J, Wijaya E, Suciadi LP, Saboe A, Cool CJ.

Title: Cytokine release syndrome is not usually caused by secondary hemophagocytic lymphohistiocytosis in a cohort of 19 critically ill COVID-19 patients

Lorenz G, Moog P, Bachmann Q, La Rosée P, Schneider H, Schlegl M, Spinner C, Heemann U, Schmid RM, Algül H, Lahmer T, Huber W, Schmaderer C.

Biochemical and immunological aspects of Covid-19 infection and therapeutical intervention of oral low dose cytokine therapy: A systematic review

M R, S S, Jose SP, Rajan S, Thomas S, Jagmag T, Tilwani J.

Probiotics in Treatment of Viral Respiratory Infections and Neuroinflammatory Disorders

Shahbazi R, Yasavoli-Sharahi H, Alsadi N, Ismail N, Matar C.

Pediatric Inflammatory Multisystem Syndrome (PIMS) Did Occur in Poland during Months with Low COVID-19 Prevalence, Preliminary Results of a Nationwide Register

Okarska-Napierała M, Ludwikowska KM, Szenborn L, Dudek N, Mania A, Buda P, Książyk J, Mazur-Malewska K, Figlerowicz M, Szczukocki M, Kucińska B, Werner B, Stopyra L, Czech A, Berdej-Szczot E, Gawlik A, Opalińska P, Mazur A, Januszkiewicz-Lewandowska D, Niszczota C, Jackowska T, Wysocki J, Mois CoR Study Group, Kuchar E.

Eosinophilic esophagitis: is the Th2 inflammation protective against the severe form of COVID-19?

Franceschini L, Macchiarelli R, Rentini S, Biviano I, Farsi A.

Characteristics of Pediatric Inflammatory Multisystem Syndrome Associated with COVID-19

Rosenberg K.

Anti-inflammatory substances from onions could be an option for treatment of COVID-19-a hypothesis

Dorsch W, Ring J.

Change of Antigenic Determinants of SARS-CoV-2 Virus S-Protein as a Possible Cause of Antibody-Dependent Enhancement of Virus Infection and Cytokine Storm

Nechipurenko YD, Anashkina AA, Matveeva OV.

COVID-19: A Case for Inhibiting NLRP3 Inflammasome, Suppression of Inflammation with Curcumin?

Saeedi-Boroujeni A, Mahmoudian-Sani MR, Bahadoram M, Alghasi A.

Guillian Barré syndrome and COVID-19: Possible role of the cytokine storm

Hussain FS, Eldeeb MA, Blackmore D, Siddiqi ZA.

Cardiac injury prediction and lymphocyte immunity and inflammation analysis in hospitalized patients with coronavirus disease 2019 (COVID-19)

Zhou W, Song L, Wang X, Xu Z, Wang S, Wang J, Xu H, Zheng Y, Wang Y.

Neuroprotective effects of flavone luteolin in neuroinflammation and neurotrauma

Kempuraj D, Thangavel R, Kempuraj DD, Ahmed ME, Selvakumar GP, Raikwar SP, Zaheer SA, Iyer SS, Govindarajan R, Chandrasekaran PN, Zaheer A.

Potency and timing of antiviral therapy as determinants of duration of SARS-CoV-2 shedding and intensity of inflammatory response

Goyal A, Cardozo-Ojeda EF, Schiffer JT.

Considerations for nutrition support in critically ill children with COVID-19 and paediatric inflammatory multisystem syndrome temporally associated with COVID-19

Marino LV, Valla FV, Tume LN, Jotterand-Chaparro C, Moullet C, Latten L, Joosten K, Verbruggen SCAT.

Overview on the use of IL-6 agents in the treatment of patients with cytokine release syndrome (CRS) and pneumonitis related to COVID-19 disease

Zhou Z, Price CC.

Patient perspectives on social-media-delivered telemedicine for inflammatory bowel disease

O'Neill P, Shandro B, Poullis A.

COVID-19-associated Multisystem Inflammatory Syndrome in Children Presenting as Acute Pancreatitis

Stevens JP, Brownell JN, Freeman AJ, Bashaw H.

Cardiac Dysfunction in Multisystem Inflammatory Syndrome in Children: A Call to Action

Friedman KG, Harrild DM, Newburger JW.

Anti-inflammatory effects of cordycepin: A review

Tan L, Song X, Ren Y, Wang M, Guo C, Guo D, Gu Y, Li Y, Cao Z, Deng Y.

Immunosuppressive Therapy and Risk of COVID-19 Infection in Patients With Inflammatory Bowel Diseases

Burke KE, Kochar B, Allegretti JR, Winter RW, Lochhead P, Khalili H, Colizzo FP, Hamilton MJ, Chan WW, Ananthakrishnan AN.

Management of COVID-19 myopericarditis with reversal of cardiac dysfunction after blunting of cytokine storm: a case report

Li A, Garcia-Bengochea Y, Stechel R, Azari BM.

Successful treatment of acute heart failure in COVID-19-induced cytokine storm with tocilizumab: a case report

Chitturi KR, Thacker S, Al-Saadi MA, Kassi M.

Ventricular tachycardia storm management in a COVID-19 patient: a case report

Mitacchione G, Schiavone M, Gasperetti A, Forleo GB.

Anisocytosis is Associated With Short-Term Mortality in COVID-19 and May Reflect Proinflammatory Signature in Uninfected Ambulatory Adults

Hornick A, Tashtish N, Osnard M, Shah B, Bradigan A, Albar Z, Tomalka J, Dalton J, Sharma A, Sekaly RP, Hejal R, Simon DI, Zidar DA, Al-Kindi SG; Inaction Study Group..

Review of inflammatory bowel disease and COVID-19

Sultan K, Mone A, Durbin L, Khuwaja S, Swaminath A.

Guidance for Restarting Inflammatory Bowel Disease Therapy in Patients Who Withheld Immunosuppressant Medications During COVID-19

Siegel CA, Christensen B, Kornbluth A, Rosh JR, Kappelman MD, Ungaro RC, Johnson DF, Chapman S, Wohl DA, Mantzaris GJ.

International Organization for the Study of Inflammatory Bowel Disease: Global Strategies for Telemedicine and Inflammatory Bowel Diseases

Lewin S, Lees C, Regueiro M, Hart A, Mahadevan U.

Management of Pregnant Inflammatory Bowel Disease Patients During the COVID-19 Pandemic

De Lima-Karagiannis A, Juillerat P, Sebastian S, Pedersen N, Bar-Gil Shitrit A, van der Woude CJ.

Multisystem Inflammatory Syndrome in Children in the United States

Belot A, Levy-Bruhl D; French Covid-19 Pediatric Inflammation Consortium.

The Cross-Talk between Age, Hypertension and Inflammation in COVID-19 Patients: Therapeutic Targets

Casucci G, Acanfora D, Incalzi RA.

Does inflammation help during COVID-19?

Sharma L, Chang D, Dela Cruz CS.

COVID-19 in a Patient Treated for Granulomatosis with Polyangiitis: Persistent Viral Shedding with No Cytokine Storm

Daniel P, Raad M, Waked R, Choucair J, Riachy M, Haddad F.

[Analysis of the changes of inflammatory cytokine levels in patients with critical coronavirus disease 2019 undergoing invasive mechanical ventilation]

Shan H, Lyu Z, Xiao Y, Li C, Wang J, He L, Chen F.

Influence of anti-osteoporosis treatments on the incidence of COVID-19 in patients with non-inflammatory rheumatic conditions

Blanch-Rubió J, Soldevila-Domenech N, Tío L, Llorente-Onaindia J, Ciria-Recasens M, Polino L, Gurt A, de la Torre R, Maldonado R, Monfort J, Group TCS.

Cholesterol, inflammation, and phospholipids: COVID-19 share traits with cardiovascular disease

Pimentel LL, Rodríguez-Alcalá LM.

COVID-19-Associated Coagulopathy and Inflammatory Response: What Do We Know Already and What Are the Knowledge Gaps?

Görlinger K, Dirkmann D, Gandhi A, Simioni P.

COVID-19 Coagulopathy and Inflammation: The Knowns and Unknowns

Wanderer JP, Nathan N.

Clinical Outcomes of Covid-19 in Patients with Inflammatory Bowel Disease: A Nationwide Cohort Study

Derikx LAAP, Lantinga MA, de Jong DJ, van Dop WA, Creemers RH, Römkens TEH, Jansen JM, Mahmmod N, West RL, Tan ACITL, Bodelier AGL, Gorter MHP, Boekema PJ, Halet ERC, Horjus CS, van Dijk MA, Hirdes MMC, Epping Stippel LSM, Jharap B, Lutgens MWMD, Russel MG, Gilissen LPL, Nauta S, van Bodegraven AA, Hoentjen F.

New Insights on COVID-19's Hyperinflammation in Children

Kuehn BM.

Toll-like receptors in sepsis-associated cytokine storm and their endogenous negative regulators as future immunomodulatory targets

Kumar V.

The unfinished story of hydroxychloroquine in COVID-19: the right anti-inflammatory dose at the right moment?

Dauby N, Bottieau E.

COVID-19 Associated Multisystem Inflammatory Syndrome in Children (MIS-C): a novel disease that mimics Toxic Shock Syndrome. The superantigen hypothesis

Rivas MN, Porritt RA, Cheng MH, Bahar I, Arditi M.

Comparative Survival Analysis of Immunomodulatory Therapy for COVID-19 'Cytokine Storm'

Narain S, Stefanov DG, Chau AS, Weber AG, Marder G, Kaplan B, Malhotra P, Bloom O, Liu A, Lesser ML, Hajizadeh N; Northwell COVID-19 Research Consortium.

Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes

Leisman DE, Ronner L, Pinotti R, Taylor MD, Sinha P, Calfee CS, Hirayama AV, Mastroiani F, Turtle CJ, Harhay MO, Legrand M, Deutschman CS.

Private Tour Guide to Pediatric Coronavirus Disease of 2019 and Multisystem Inflammatory Syndrome in Children in 10 Minutes: What Thoracic Radiologists Need to Know

Foust AM, Winant AJ, Restrepo R, Liszewski MC, Plut D, Lee EY.

Infusion of HLA-matched and static magnetic field-exposed allogenic lymphocytes treating lymphocytopenia and cytokine storm syndrome: A treatment proposal for COVID-19 patients

Vergallo C.

Why Do Immunosuppressed Patients with Inflammatory Bowel Disease Not Seem to Be at a Higher Risk of COVID-19?

Scribano ML.

Imperfect storm: is interleukin-33 the Achilles heel of COVID-19?

Zizzo G, Cohen PL.

Rapid Response to Cytokine Storm Inhibition using Anakinra in a Patient with COVID-19 Myocarditis

Trpkov C, MacMullan P, Feuchter P, Kachra R, Heydari B, Merchant N, Bristow MS, White JA.

The role of inflammation in hypertension: novel concepts

Patrick DM, Van Beusecum JP, Kirabo A.

Systematic Analyses on the Potential Immune and anti-inflammatory Mechanisms of Shufeng Jiedu Capsule against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-caused Pneumonia

Tao Z, Zhang L, Friedemann T, Yang G, Li J, Wen Y, Wang J, Shen A.

COVID-19: In the Eye of the Cytokine Storm

de la Rica R, Borges M, Gonzalez-Freire M.

Anti-IL-6 Versus Anti-IL-6R Blocking Antibodies to Treat Acute Ebola Infection in BALB/c Mice: Potential Implications for Treating Cytokine Release Syndrome

Rubsamen R, Burkholz S, Massey C, Brasel T, Hodge T, Wang L, Herst C, Carback R, Harris P.

Activities related to inflammatory bowel disease management during and after the coronavirus disease 2019 lockdown in Italy: How to maintain standards of care

Saibeni S, Scucchi L, Dragoni G, Bezzio C, Miranda A, Ribaldone DG, Bertani A, Bossa F, Allocca M, Buda A, Mocci G, Soriano A, Mazzuoli S, Bertani L, Baccini F, Loddo E, Privitera AC, Sartini A, Viscido A, Grossi L, Casini V, Gerardi V, Ascolani M, Ruscio MD, Casella G, Savarino E, Stradella D, Pumpo R, Cortelezzi CC, Daperno M, Ciardo V, Nardone OM, Caprioli F, Vitale G, Cappello M, Comberlato M, Alvisi P, Festa S, Campigotto M, Bodini G, Balestrieri P, Viola A, Pugliese D, Armuzzi A, Fantini M

Endothelial dysfunction contributes to COVID-19-associated vascular inflammation and coagulopathy

Zhang J, Tecson KM, McCullough PA.

Bracing for the Storm: One Health Care System's Planning for the COVID-19 Surge

Kim CS, Meo N, Little D, Morris SC, Brandenburg LA, Moratti M, Dold CL, Staiger TO, Sayre C, Goss JR, Dayao JM, Dellit TH.

Pro resolving inflammatory effects of the lipid mediators of omega 3 fatty acids and its implication in SARS COVID-19

Regidor PA, Santos FG, Rizo JM, Egea FM.

Proinflammatory cytokines are associated with prolonged viral RNA shedding in COVID-19 patients

Gao C, Zhu L, Jin CC, Tong YX, Xiao AT, Zhang S.

Correction: Ivermectin may be a clinically useful anti-inflammatory agent for late-stage COVID-19

Defining the Cytokine Storm Syndrome of COVID-19: Role of the Clinical Laboratory

Jialal I, Devaraj S.

Use of the interleukin 6 inhibitor tocilizumab in Japanese patients with cytokine release syndrome caused by COVID-19-related acute respiratory distress syndrome: A case series

Nakamura H, Miyagi K, Otsuki M, Higure Y, Nishiyama N, Kinjo T, Nakamatsu M, Haranaga S, Tateyama M, Fujita J.

Presentation, Treatment Response and Short-Term Outcomes in Paediatric Multisystem Inflammatory Syndrome Temporally Associated with SARS-CoV-2 (PIMS-TS)

Felsenstein S, Willis E, Lythgoe H, McCann L, Cleary A, Mahmood K, Porter D, Jones J, McDonagh J, Chieng A, Varnier G, Hughes S, Boullier M, Ryan F, Awogbemi O, Soda G, Duong P, Pain C, Riley P, Hedrich CM.

SARS-CoV-2 mediated lung inflammatory responses in host: targeting the cytokine storm for therapeutic interventions

Asrani P, Hassan MI.

[Fatal course of COVID-19 despite IL-6 receptor blockade in cytokine storm : Perimyocarditis and coagulopathy after administration of tocilizumab]

Bovet M, Wadsack D, Kosely F, Zink W, Zahn R.

Unraveling the Role of ACE2, the Binding Receptor for SARS-CoV-2, in Inflammatory Bowel Disease

Ferreira-Duarte M, Estevinho MM, Duarte-Araújo M, Magro F, Morato M.

Understanding attitudes, concerns and health behaviours of patients with inflammatory bowel disease during the COVID-19 pandemic

Goodsall TM, Han S, Bryant RV.

ECCO2R with cytokine filtering in COVID-19 patients: Who wants to go down this road?

Condello I, Mastroroberto P, Santarpino G.

Fecal occult blood and urinary cytology tests for rapid screening of inflammatory infection in the gastrointestinal and urological systems in patients with Coronavirus disease 2019

Du L, Cao X, Chen J, Wei X, Zeng Y, Cheng C, Lin Y, Tan W, Wang H.

Elucidating the Pivotal Immunomodulatory and Anti-Inflammatory Potentials of Chloroquine and Hydroxychloroquine

Richard SA, Kampo S, Hechavarria ME, Sackey M, Buunaaim ADB, Kuugbee ED, Anabah TW.

The Symptoms and Medications of Patients with Inflammatory Bowel Disease in Hubei Province after COVID-19 Epidemic

Wang H, Tu L, Li Y, Bai T, Zou K, Xiao F, Li J, Chen M, Zhang H, Li G, Lu Y, Wang K, Jin S, Yang Y, Zhu L, Hou X.

Serum Cystatin C and Coronavirus Disease 2019: A Potential Inflammatory Biomarker in Predicting Critical Illness and Mortality for Adult Patients

Chen D, Sun W, Li J, Wei B, Liu W, Wang X, Song F, Chen L, Yang J, Yu L.

COVID-19 and intestinal inflammation: Role of fecal calprotectin

Ojetti V, Saviano A, Covino M, Acampora N, Troiani E, Franceschi F; GEMELLI AGAINST COVID‐19 group.

Harnessing the immune system to overcome cytokine storm and reduce viral load in COVID-19: a review of the phases of illness and therapeutic agents

Khadke S, Ahmed N, Ahmed N, Ratts R, Raju S, Gallogly M, de Lima M, Sohail MR.

Growth Differentiation Factor-15 Provides Prognostic Information Superior to Established Cardiovascular and Inflammatory Biomarkers in Unselected Patients Hospitalized with COVID-19

Myhre PL, Prebensen C, Strand H, Røysland R, Jonassen CM, Rangberg A, Sørensen V, Søvik S, Røsjø H, Svensson M, Berdal JE, Omland T.

Deciphering the COVID-19 cytokine storm: Systematic review and meta-analysis

Mulchandani R, Lyngdoh T, Kumar Kakkar A.

COVID-19 and Multisystem Inflammatory Syndrome in Latin American Children: A Multinational Study

Antúnez-Montes OY, Escamilla MI, Figueroa-Uribe AF, Arteaga-Menchaca E, Lavariega-Saráchaga M, Salcedo-Lozada P, Melchior P, de Oliveira RB, Tirado Caballero JC, Redondo HP, Montes Fontalvo LV, Hernandez R, Chavez C, Campos F, Uribe F, Del Aguila O, Rios Aida JA, Buitrago AP, Betancur Londoño LM, Mendoza Vega LF, Hernández CA, Sali M, Higuita Palacio JE, Gomez-Vargas J, Yock-Corrales A, Buonsenso D.

COVID-19: pressure ulcers, pain and the cytokine storm

Gefen A, Ousey K.

SARS-CoV-2 morbidity and mortality in racial/ethnic minority populations: A window into the stress related inflammatory basis of health disparities?

Gelaye B, Foster S, Bhasin M, Tawakol A, Fricchione G.

Platelets Promote Thromboinflammation in SARS-CoV-2 Pneumonia

Taus F, Salvagno G, Canè S, Fava C, Mazzaferri F, Carrara E, Petrova V, Barouni RM, Dima F, Dalbeni A, Romano S, Poli G, Benati M, Denitto S, Mansueto G, Iezzi M, Tacconelli E, Lippi G, Bronte V, Minuz P.

Attenuating COVID-19 infection and inflammation: Lessons from asthma

Bardin PG, Johnston SL.

A Cytokine Circus with a Viral Ringleader: SARS-CoV-2-Associated Cytokine Storm Syndromes

Cabler SS, French AR, Orvedahl A.

Considerations on the Article «Antiviral and Anti-Inflammatory Properties of Ivermectin and its Potential Use in COVID-19»

Hernández-Vásquez A, Vargas-Fernández R, Azañedo D.

CASCADE: a phase 2, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the effect of tezepelumab on airway inflammation in patients with uncontrolled asthma

Emson C, Diver S, Chachi L, Megally A, Small C, Downie J, Parnes JR, Bowen K, Colice G, Brightling CE.

Pentoxifylline, a drug with antiviral, anti-inflammatory and bronchodilatory effects may be a possible drug candidate for SARS-CoV-2

Ghasemnejad-Berenji M, Pashapour S, Sadeghpour S.

Advancement in biosensors for inflammatory biomarkers of SARS-CoV-2 during 2019-2020

Garg M, Sharma AL, Singh S.

Type 2 and interferon inflammation regulate SARS-CoV-2 entry factor expression in the airway epithelium

Sajuthi SP, DeFord P, Li Y, Jackson ND, Montgomery MT, Everman JL, Rios CL, Pruesse E, Nolin JD, Plender EG, Wechsler ME, Mak ACY, Eng C, Salazar S, Medina V, Wohlford EM, Huntsman S, Nickerson DA, Germer S, Zody MC, Abecasis G, Kang HM, Rice KM, Kumar R, Oh S, Rodriguez-Santana J, Burchard EG, Seibold MA.

Blood purification therapy with a hemodiafilter featuring enhanced adsorptive properties for cytokine removal in patients presenting COVID-19: a pilot study

Villa G, Romagnoli S, De Rosa S, Greco M, Resta M, Pomarè Montin D, Prato F, Patera F, Ferrari F, Rotondo G, Ronco C.

Novel serological biomarkers for inflammation in predicting disease severity in patients with COVID-19

Xue G, Gan X, Wu Z, Xie D, Xiong Y, Hua L, Zhou B, Zhou N, Xiang J, Li J.

Cytokine profile and disease severity in patients with COVID-19

Ghazavi A, Ganji A, Keshavarzian N, Rabiemajd S, Mosayebi G.

Steroids for sepsis and ARDS: this eternal controversy remains with COVID-19

Carlet J, Payen D, Opal SM.

Beyond COVID-19-a paradigm shift in infection management?

Vehreschild MJGT, Tacconelli E, Giske CG, Peschel A.

COVID-19 Pandemic's Effects on Disease and Psychological Outcomes of People With Inflammatory Bowel Disease in Portugal: A Preliminary Research

Trindade IA, Ferreira NB.

Biological Therapy for Inflammatory Bowel Disease During the COVID-19 Pandemic: Experiences From a Tertiary IBD Service

Markovic S, Ivanovski TK, Zogovic B, Cvetkovic M, Svorcan P.

Viral arthritis and COVID-19

Parisi S, Borrelli R, Bianchi S, Fusaro E.

Kawasaki Disease and Multisystem Inflammatory Syndrome in Children with COVID-19

Sarzaeim M, Rezaei N.

Thrombo-inflammation response to Tocilizumab in COVID-19

Gergi M, Cushman M, Littenberg B, Budd RC.

Seasonality of Respiratory Viral Infections: Will COVID-19 Follow Suit?

Audi A, AlIbrahim M, Kaddoura M, Hijazi G, Yassine HM, Zaraket H.

Pediatric Inflammatory Multisystem Syndrome Temporally Related With SARS-CoV-2: Immunological Similarities With Acute Rheumatic Fever and Toxic Shock Syndrome

Buonsenso D, Riitano F, Valentini P.

Retrospective Analysis of Inflammatory Markers and Patient Characteristics in Hospitalized Covid-19 Patients: An Early Experience in Louisiana

Miatech JL, Yaslik CP, Tarleton HE, West D, Kellum W, McKnight M, Stagg MP.

Oral Candidiasis in Non-Severe COVID-19 Patients: Call for Antibiotic Stewardship

Riad A, Gad A, Hockova B, Klugar M.

COVID-19: Infection or Autoimmunity

Icenogle T.

In Silico Prediction of Molecular Targets of Astragaloside IV for Alleviation of COVID-19 Hyperinflammation by Systems Network Pharmacology and Bioinformatic Gene Expression Analysis

Ge C, He Y.

Cytosorb filter: An adjunct for survival in the COVID-19 patient in cytokine storm? a case report

Rizvi S, Danic M, Silver M, LaBond V.

Transcription Factor Nrf2 as a Potential Therapeutic Target for Prevention of Cytokine Storm in COVID-19 Patients

Zinovkin RA, Grebenchikov OA.

Stem Cell Transplantation Therapy: A Potential Method for Treating Cytokine Storm Syndromes Induced by COVID-19

Wang HC, Wang X, Long X.

COVID-19 infection induces readily detectable morphologic and inflammation-related phenotypic changes in peripheral blood monocytes

Zhang D, Guo R, Lei L, Liu H, Wang Y, Wang Y, Qian H, Dai T, Zhang T, Lai Y, Wang J, Liu Z, Chen T, He A, O'Dwyer M, Hu J.

Decreased complement C3 levels are associated with poor prognosis in patients with COVID-19: A retrospective cohort study

Fang S, Wang H, Lu L, Jia Y, Xia Z.

Dysimmunity and inflammatory storm: Watch out for bone lesions in COVID-19 infection

Tao H, Ge G, Li W, Liang X, Wang H, Li N, Sun H, Zhang W, Geng D.

Anti-Inflammatory Drugs and the Renin-Angiotensin-Aldosterone System: Current Knowledge and Potential Effects on Early SARS-CoV-2 Infection

Cabbab ILN, Manalo RVM.

Cytokine Storms in Cancer and COVID-19

Turnquist C, Ryan BM, Horikawa I, Harris BT, Harris CC.

Polyunsaturated fatty acid biosynthesis pathway and genetics. implications for interindividual variability in prothrombotic, inflammatory conditions such as COVID-19(✰,✰✰,★,★★)

Kothapalli KSD, Park HG, Brenna JT.

COVID-19 induced ARDS, and the use of galantamine to activate the cholinergic anti-inflammatory pathway

Ahmad F.

Targeting pivotal inflammatory pathways in COVID-19: A mechanistic review

Yarmohammadi A, Yarmohammadi M, Fakhri S, Khan H.

SARS-CoV-2 triggers inflammatory responses and cell death through caspase-8 activation

Li S, Zhang Y, Guan Z, Li H, Ye M, Chen X, Shen J, Zhou Y, Shi ZL, Zhou P, Peng K.

Addendum to S3-Guidelines Crohn's disease and ulcerative colitis: Management of Patients with Inflammatory Bowel Disease in the COVID-19 Pandemic - open questions and answers

Stallmach A, Sturm A, Blumenstein I, Helwig U, Koletzko S, Lynen P, Schmidt C, Dignass A, Kucharzik T; Collaborators:.

COVID-19 in children: a case report of Multisystem Inflammatory Syndrome (MIS-C) in São Paulo, Brazil

Matsuda EM, Santos SAD, Castejon MJ, Ahagon CM, Campos IB, Brígido LFM.

Prevalence and outcomes of COVID-19 among patients with inflammatory bowel disease - A Danish prospective population-based cohort study

Attauabi M, Poulsen A, Theede K, Pedersen N, Larsen L, Jess T, Rosager Hansen M, Kajbæk Verner-Andersen M, V Haderslev K, Berg Lødrup A, Molazahi A, Neumann A, Wase A, Seidelin JB, Burisch J.

Immune reconstitution and clinical recovery following anti-CD28 antibody (TGN1412)-induced cytokine storm

Panoskaltsis N, McCarthy NE, Stagg AJ, Mummery CJ, Husni M, Arebi N, Greenstein D, Price CL, Al-Hassi HO, Koutinas M, Mantalaris A, Knight SC.

The four epidemiological stages in the global evolution of inflammatory bowel disease

Kaplan GG, Windsor JW.

Endothelial glycocalyx damage as a systemic inflammatory microvascular endotheliopathy in COVID-19

Yamaoka-Tojo M.

In-hospital mortality is associated with inflammatory response in NAFLD patients admitted for COVID-19

Forlano R, Mullish BH, Mukherjee SK, Nathwani R, Harlow C, Crook P, Judge R, Soubieres A, Middleton P, Daunt A, Perez-Guzman P, Selvapatt N, Lemoine M, Dhar A, Thursz MR, Nayagam S, Manousou P.

Case Series of Multisystem Inflammatory Syndrome in Adults Associated with SARS-CoV-2 Infection - United Kingdom and United States, March-August 2020

Morris SB, Schwartz NG, Patel P, Abbo L, Beauchamps L, Balan S, Lee EH, Paneth-Pollak R, Geevarughese A, Lash MK, Dorsinville MS, Ballen V, Eiras DP, Newton-Cheh C, Smith E, Robinson S, Stogsdill P, Lim S, Fox SE, Richardson G, Hand J, Oliver NT, Kofman A, Bryant B, Ende Z, Datta D, Belay E, Godfred-Cato S.

Inflammation Triggered by SARS-CoV-2 and ACE2 Augment Drives Multiple Organ Failure of Severe COVID-19: Molecular Mechanisms and Implications

Iwasaki M, Saito J, Zhao H, Sakamoto A, Hirota K, Ma D.

Telemedicine and Remote Screening for COVID-19 in Inflammatory Bowel Disease Patients: Results From the SoCOVID-19 Survey

Fantini MC, Biancone L, Dragoni G, Bezzio C, Miranda A, Ribaldone DG, Bertani A, Bossa F, Allocca M, Buda A, Mocci G, Soriano A, Guglielmi FW, Bertani L, Baccini F, Loddo E, Privitera AC, Sartini A, Viscido A, Grossi L, Casini V, Gerardi V, Ascolani M, Di Ruscio M, Casella G, Savarino E, Stradella D, Pumpo R, Cortelezzi CC, Daperno M, Ciardo V, Nardone OM, Caprioli F, Vitale G, Cappello M, Comberlato M, Alvisi P, Festa S, Campigotto M, Bodini G, Balestrieri P, Viola A, Pugliese D, Armuzzi A, Sai

Cytokine Storm in COVID-19 Patients, Its Impact on Organs and Potential Treatment by QTY Code-Designed Detergent-Free Chemokine Receptors

Mustafa MI, Abdelmoneim AH, Mahmoud EM, Makhawi AM.

A Canadian perspective on severe acute respiratory syndrome coronavirus 2 infection and treatment: how prevalent underlying inflammatory disease contributes to pathogenesis

Willows SD, Alam SB, Sandhu JK, Kulka M.

Inflammation of papillae of Wharton's duct in COVID-19 patients: A debatable entity

Afsal AS, Musthafa N, Fathima MS, Lakshmi GG.

Low-Dose Dexamethasone Following IVIG in Pediatric Inflammatory Multisystem Syndrome in Temporal Association with COVID-19 (PIMS-TC)

Meena P, Pallavi, Mishra D, Jhamb U, Aggarwal M.

The impact of a dedicated contact centre on the clinical outcome of patients with inflammatory bowel disease during the COVID-19 outbreak

Nardone OM, Rispo A, Testa A, Imperatore N, Pellegrini L, Guarino AD, Ricciolino S, Patturelli M, De Palma G, Castiglione F.

Decoy nanoparticles protect against COVID-19 by concurrently adsorbing viruses and inflammatory cytokines

Rao L, Xia S, Xu W, Tian R, Yu G, Gu C, Pan P, Meng QF, Cai X, Qu D, Lu L, Xie Y, Jiang S, Chen X.

COVID-19 and Multisystem Inflammatory Syndrome, or is it Mast Cell Activation Syndrome?

Theoharides TC, Conti P.

Microcirculatory, Endothelial and Inflammatory Responses in Critically Ill Patients with COVID-19 are Distinct from those Seen in Septic Shock: A Case Control Study

Hutchings SD, Watchorn J, Trovato F, Napoli S, Mujib SF, Hopkins P, McPhail M.

In the Eye of the Storm: Bioethics in the Time of COVID-19

MacKenzie CR, Green DST, Chisholm MF, Waldman SA.

The Management of Cytokine Storm in COVID-19

Rumende CM, Susanto EC, Sitorus TP.

Inflammatory markers in gynecologic oncology patients hospitalized with COVID-19 infection

Smith M, Lara OD, O'Cearbhaill R, Knisely A, McEachron J, Gabor L, Carr C, Blank S, Prasad-Hayes M, Frey M, Jee J, Fehniger J, Wang Y, Lee YC, Isani S, Wright JD, Pothuri B.

Gut Microbiota Dysbiosis-Immune Hyperresponse-Inflammation Triad in Coronavirus Disease 2019 (COVID-19): Impact of Pharmacological and Nutraceutical Approaches

Ferreira C, Viana SD, Reis F.

Filling the gaps on stroke research: focus on inflammation and immunity

Levard D, Buendia I, Lanquetin A, Glavan M, Vivien D, Rubio M.

The calm after the storm: re-starting ART treatments safely in the wake of the COVID-19 pandemic

ESHRE COVID-19 Working Group, Gianaroli L, Ata B, Lundin K, Rautakallio-Hokkanen S, Tapanainen JS, Vermeulen N, Veiga A, Mocanu E.

Patterns of organizing pneumonia and microinfarcts as surrogate for endothelial disruption and microangiopathic thromboembolic events in patients with coronavirus disease 2019

Martini K, Blüthgen C, Walter JE, Nguyen-Kim TDL, Thienemann F, Frauenfelder T.

Use of Nonsteroidal Anti-inflammatory Drugs for COVID-19 Infection: Adjunct Therapy?

Zhao D, Zhang S, Igawa T, Frishman W.

[SARS-CoV-2 (COVID-19) as a predictor of neuroinflammation and neurodegeneration: potential therapy strategies]

Putilina MV, Grishin DV.

Coronavirus-19 (SARS-CoV-2) induces acute severe lung inflammation via IL-1 causing cytokine storm in COVID-19: a promising inhibitory strategy

Conti P, Caraffa A, Gallenga CE, Ross R, Kritas SK, Frydas I, Younes A, Ronconi G.

Clinical criteria for COVID-19-associated hyperinflammatory syndrome: a cohort study

Webb BJ, Peltan ID, Jensen P, Hoda D, Hunter B, Silver A, Starr N, Buckel W, Grisel N, Hummel E, Snow G, Morris D, Stenehjem E, Srivastava R, Brown SM.

Defining the scourge of COVID-19 hyperinflammatory syndrome

Cron RQ, Schulert GS, Tattersall RS.

Biosurfactants and anti-inflammatory activity: A potential new approach towards COVID-19

Subramaniam MD, Venkatesan D, Iyer M, Subbarayan S, Govindasami V, Roy A, Narayanasamy A, Kamalakannan S, Gopalakrishnan AV, Thangarasu R, Kumar NS, Vellingiri B.

COVID-19: Proposing a Ketone-Based Metabolic Therapy as a Treatment to Blunt the Cytokine Storm

Bradshaw PC, Seeds WA, Miller AC, Mahajan VR, Curtis WM.

How COVID-19 induces cytokine storm with high mortality

Hojyo S, Uchida M, Tanaka K, Hasebe R, Tanaka Y, Murakami M, Hirano T.

Letter to the Editor: Toll-Like Receptor Antagonists as a Potential Therapeutic Strategy Against Cytokine Storm in COVID-19-Infected Patients

Safaei S, Karimi-Googheri M.

Finding the right time for anti-inflammatory therapy in COVID-19

de Simone G, Mancusi C.

Control of systemic inflammation throughearly nitric oxide supplementation with nitric oxide releasing nanoparticles

Williams AT, Muller CR, Govender K, Navati MS, Friedman AJ, Friedman JM, Cabrales P.

Multisystem Inflammatory Syndrome in Children (MIS-C) in an Adolescent that Developed Coronary Aneurysms: A Case Report and Review of the Literature

Nelson C, Ishimine P, Hayden SR, Correia M, Wardi G.

COVID-19-Related Multisystem Inflammatory Syndrome in Children Affects Left Ventricular Function and Global Strain Compared with Kawasaki Disease

Gaitonde M, Ziebell D, Kelleman MS, Cox DE, Lipinski J, Border WL, Sachdeva R.

SARS-CoV2-mediated suppression of NRF2-signaling reveals potent antiviral and anti-inflammatory activity of 4-octyl-itaconate and dimethyl fumarate

Olagnier D, Farahani E, Thyrsted J, Blay-Cadanet J, Herengt A, Idorn M, Hait A, Hernaez B, Knudsen A, Iversen MB, Schilling M, Jørgensen SE, Thomsen M, Reinert LS, Lappe M, Hoang HD, Gilchrist VH, Hansen AL, Ottosen R, Nielsen CG, Møller C, van der Horst D, Peri S, Balachandran S, Huang J, Jakobsen M, Svenningsen EB, Poulsen TB, Bartsch L, Thielke AL, Luo Y, Alain T, Rehwinkel J, Alcamí A, Hiscott J, Mogensen T, Paludan SR, Holm CK.

Biomarkers of Cytokine Release Syndrome Predict Disease Severity and Mortality From COVID-19 in Kidney Transplant Recipients

Benotmane I, Perrin P, Gautier Vargas G, Bassand X, Keller N, Lavaux T, Ohana M, Bedo D, Baldacini C, Sagnard M, Bozman DF, Della Chiesa M, Cognard N, Olagne J, Delagreverie H, Marx D, Heibel F, Braun L, Moulin B, Fafi Kremer S, Caillard S.

Review on therapeutic targets for COVID-19: insights from cytokine storm

Mélo Silva Júnior ML, Souza LMA, Dutra REMC, Valente RGM, Melo TS.

Inflammation and Intussusceptive Angiogenesis in COVID-19: everything in and out of Flow

Ackermann M, Mentzer SJ, Kolb M, Jonigk D.

"Cytokine storm", not only in COVID-19 patients. Mini-review

Lukan N.

Being caught in the perfect storm of a diabetes epidemic and the COVID-19 pandemic: What should we do for our patients?

Cho Y, Yoon KH.

Our 5-year experience of a new inflammatory teledermoscopy service

Lowe A, Stone NM.

In-silico drug repurposing study predicts the combination of pirfenidone and melatonin as a promising candidate therapy to reduce SARS-CoV-2 infection progression and respiratory distress caused by cytokine storm

Artigas L, Coma M, Matos-Filipe P, Aguirre-Plans J, Farrés J, Valls R, Fernandez-Fuentes N, de la Haba-Rodriguez J, Olvera A, Barbera J, Morales R, Oliva B, Mas JM.

COVID-19 pandemic and Inflammatory Bowel Disease: patient perception at the time of telemedicine

Zingone F, Siniscalchi M, Savarino EV, Barberio B, Cingolani L, D'Incà R, De Filippo FR, Camera S, Ciacci C.

Oxidative Stress and Inflammation in COVID-19-Associated Sepsis: The Potential Role of Anti-Oxidant Therapy in Avoiding Disease Progression

Beltrán-García J, Osca-Verdegal R, Pallardó FV, Ferreres J, Rodríguez M, Mulet S, Sanchis-Gomar F, Carbonell N, García-Giménez JL.

Disharmonic Inflammatory Signatures in COVID-19: Augmented Neutrophils' but Impaired Monocytes' and Dendritic Cells' Responsiveness

Parackova Z, Zentsova I, Bloomfield M, Vrabcova P, Smetanova J, Klocperk A, Mesežnikov G, Casas Mendez LF, Vymazal T, Sediva A.

Rhamnocitrin extracted from Nervilia fordii inhibited vascular endothelial activation via miR-185/STIM-1/SOCE/NFATc3

Lin T, Luo W, Li Z, Zhang L, Zheng X, Mai L, Yang W, Guan G, Su Z, Liu P, Li Z, Xie Y.

Prognostic value of interleukin-18 and its association with other inflammatory markers and disease severity in COVID-19

Satış H, Özger HS, Aysert Yıldız P, Hızel K, Gulbahar Ö, Erbaş G, Aygencel G, Guzel Tunccan O, Öztürk MA, Dizbay M, Tufan A.

Does intestinal dysbiosis contribute to an aberrant inflammatory response to severe acute respiratory syndrome coronavirus 2 in frail patients?

Terruzzi I, Senesi P.

Inflammation and thrombosis in patients with COVID-19: A prothrombotic and inflammatory disease caused by SARS coronavirus-2

Pamukçu B.

Fever Patterns, Cytokine Profiles, and Outcomes in COVID-19

Ng DHL, Choy CY, Chan YH, Young BE, Fong SW, Ng LFP, Renia L, Lye DC, Chia PY; National Centre for Infectious Diseases COVID-19 Outbreak Research Team.

Mild COVID-19 Symptoms in an Infliximab-Treated Ulcerative Colitis Patient: Can Ongoing Anti-TNF Therapy Protect against the Viral Hyperinflammatory Response and Avoid Aggravated Outcomes?

Abdullah A, Neurath MF, Atreya R.

Inflammatory leptomeningeal cytokines mediate delayed COVID-19 encephalopathy

Remsik J, Wilcox JA, Babady NE, McMillen T, Vachha BA, Halpern NA, Dhawan V, Rosenblum M, Iacobuzio-Donahue CA, Avila EK, Santomasso B, Boire A.

Baricitinib treatment resolves lower airway inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques

Hoang TN, Pino M, Boddapati AK, Viox EG, Starke CE, Upadhyay AA, Gumber S, Busman-Sahay K, Strongin Z, Harper JL, Tharp GK, Pellegrini KL, Kirejczyk S, Zandi K, Tao S, Horton TR, Beagle EN, Mahar EA, Lee MY, Cohen J, Jean SM, Wood JS, Connor-Stroud F, Stammen RL, Delmas OM, Wang S, Cooney KA, Sayegh MN, Wang L, Weiskopf D, Filev PD, Waggoner J, Piantadosi A, Kasturi SP, Shakhshir HA, Ribeiro SP, Sekaly RP, Levit RD, Estes JD, Vanderford TH, Schinazi RF, Bosinger SE, Paiardini M.

COVID-19-Induced Cytokine Release Syndrome Associated with Pulmonary Vein Thromboses, Atrial Cardiomyopathy, and Arterial Intima Inflammation

Goette A, Patscheke M, Henschke F, Hammwöhner M.

A young adult with COVID-19 and multisystem inflammatory syndrome in children (MIS-C)-like illness: a case report

Kofman AD, Sizemore EK, Detelich JF, Albrecht B, Piantadosi AL.

Insult to injury- potential contribution of COVID-19 to neuroinflammation and the development of HIV-associated neurocognitive disorders

Williams ME, Fielding BC.

Endothelial Cell Contributions to COVID-19

Oxford AE, Halla F, Robertson EB, Morrison BE.

Mapping Systemic Inflammation and Antibody Responses in Multisystem Inflammatory Syndrome in Children (MIS-C)

Gruber CN, Patel RS, Trachtman R, Lepow L, Amanat F, Krammer F, Wilson KM, Onel K, Geanon D, Tuballes K, Patel M, Mouskas K, O'Donnell T, Merritt E, Simons NW, Barcessat V, Del Valle DM, Udondem S, Kang G, Gangadharan S, Ofori-Amanfo G, Laserson U, Rahman A, Kim-Schulze S, Charney AW, Gnjatic S, Gelb BD, Merad M, Bogunovic D.

PET in the diagnostic management of infectious/inflammatory pulmonary pathologies: a revisit in the era of COVID-19

Katal S, Amini H, Gholamrezanezhad A.

The cytokine storm - An appropriate, over-reactive response to SARS-COV-2 or the wrong immune pathway?

Bellgrau D, Modiano JF.

Diagnosis of SARS-CoV-2 infection in the setting of cytokine release syndrome

Azar MM, Shin JJ, Kang I, Landry M.

Antibody responses in COVID-19 patients

Liu S, Lu S.

COVID-19 Patients Upregulate Toll-like Receptor 4-mediated Inflammatory Signaling That Mimics Bacterial Sepsis

Sohn KM, Lee SG, Kim HJ, Cheon S, Jeong H, Lee J, Kim IS, Silwal P, Kim YJ, Paik S, Chung C, Park C, Kim YS, Jo EK.

The Antibody Response to SARS-CoV-2 Infection

Hueston L, Kok J, Guibone A, McDonald D, Hone G, Goodwin J, Carter I, Basile K, Sandaradura I, Maddocks S, Sintchenko V, Gilroy N, Chen S, Dwyer DE, O'Sullivan MVN.

The spectrum of biochemical alterations associated with organ dysfunction and inflammatory status and their association with disease outcomes in severe COVID-19: A longitudinal cohort and time-series design study

Oussalah A, Gleye S, Urmes IC, Laugel E, Barbé F, Orlowski S, Malaplate C, Aimone-Gastin I, Caillierez BM, Merten M, Jeannesson E, Kormann R, Olivier JL, Rodriguez-Guéant RM, Namour F, Bevilacqua S, Thilly N, Losser MR, Kimmoun A, Frimat L, Levy B, Gibot S, Schvoerer E, Guéant JL.

Pediatric Inflammatory Multisystem Syndrome: Statement by the Pediatric Section of the European Society for Emergency Medicine and European Academy of Pediatrics

Nijman RG, De Guchtenaere A, Koletzko B, Ross Russell R, Copley S, Titomanlio L, Del Torso S, Hadjipanayis A.

Cytokine Storm in COVID-19: "When You Come Out of the Storm, You Won't Be the Same Person Who Walked in"

Castelli V, Cimini A, Ferri C.

Intestinal inflammation modulates the expression of ACE2 and TMPRSS2 and potentially overlaps with the pathogenesis of SARS-CoV-2 related disease

Suárez-Fariñas M, Tokuyama M, Wei G, Huang R, Livanos A, Jha D, Levescot A, Irizar H, Kosoy R, Cording S, Wang W, Losic B, Ungaro R, Di'Narzo A, Martinez-Delgado G, Suprun M, Corley MJ, Stojmirovic A, Houten SM, Peters L, Curran M, Brodmerkel C, Perrigoue J, Friedman JR, Hao K, Schadt EE, Zhu J, Ko HM, Cho J, Dubinsky MC, Sands BE, Ndhlovu L, Cerf-Bensusan N, Kasarskis A, Colombel JF, Harpaz N, Argmann C, Mehandru S.

Anti-inflammatory aspects of Lidocaine: a neglected therapeutic stance for COVID-19

Maab H, Mustafa F, Arshad Ali S.

Use of tocilizumab in multisystem inflammatory syndrome in children associated with severe acute respiratory syndrome coronavirus 2

Banday AZ, Pandiarajan V.

SARS-CoV-2 Infection of Pluripotent Stem Cell-Derived Human Lung Alveolar Type 2 Cells Elicits a Rapid Epithelial-Intrinsic Inflammatory Response

Huang J, Hume AJ, Abo KM, Werder RB, Villacorta-Martin C, Alysandratos KD, Beermann ML, Simone-Roach C, Lindstrom-Vautrin J, Olejnik J, Suder EL, Bullitt E, Hinds A, Sharma A, Bosmann M, Wang R, Hawkins F, Burks EJ, Saeed M, Wilson AA, Mühlberger E, Kotton DN.

Neurological Complications Associated with the Blood-Brain Barrier Damage Induced by the Inflammatory Response During SARS-CoV-2 Infection

Alquisiras-Burgos I, Peralta-Arrieta I, Alonso-Palomares LA, Zacapala-Gómez AE, Salmerón-Bárcenas EG, Aguilera P.

Management of odontogenic infections and sepsis: an update

Jevon P, Abdelrahman A, Pigadas N.

Response to: 'Correspondence to 'Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases'' by Wu et al

Pablos JL, Galindo M, Blanco R, Alvaro-Gracia JM.

Preliminary predictive criteria for COVID-19 cytokine storm

Caricchio R, Gallucci M, Dass C, Zhang X, Gallucci S, Fleece D, Bromberg M, Criner GJ; Temple University COVID-19 Research Group.

Correspondence on 'Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort' by Pouletty et al

Ventura MJ, Guajardo E, Clark EH, Bhairavarasu K, Kherallah RY, DiNardo AR, Ye X, Piedra PA, Atmar RL, Agarwal SK.

Correspondence to 'Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases'

Wu BY, Chan CH, Wei JC.

The changes of the peripheral CD4+ lymphocytes and inflammatory cytokines in Patients with COVID-19

Sun HB, Zhang YM, Huang LG, Lai QN, Mo Q, Ye XZ, Wang T, Zhu ZZ, Lv XL, Luo YJ, Gao SD, Xu JS, Zhu HH, Li T, Wang ZK.

Are T cells helpful for COVID-19: the relationship between response and risk

Griffin DE.

Expression of ACE2 in airways: implication for COVID-19 risk and disease management in patients with chronic inflammatory respiratory diseases

Yao Y, Wang H, Liu Z.

Cardiac Findings in Pediatric Patients With Multisystem Inflammatory Syndrome in Children Associated With COVID-19

Minocha PK, Phoon CKL, Verma S, Singh RK.

Cannabis for COVID-19: can cannabinoids quell the cytokine storm?

Onaivi ES, Sharma V.

Hyperinflammation and Fibrosis in Severe COVID-19 Patients: Galectin-3, a Target Molecule to Consider

Garcia-Revilla J, Deierborg T, Venero JL, Boza-Serrano A.

Proposed use of thalidomide for the cytokine storm of COVID-19

Goihman-Yahr M.

Secondary hemophagocytic lymphohistiocytosis versus cytokine release syndrome in severe COVID-19 patients

Hakim NN, Chi J, Olazagasti C, Liu JM.

Anti-vascular endothelial growth factor treatment regimens preference by choroidal neovascularization patients under COVID-19

Au SCL.

Cardiac inflammation in COVID-19: Lessons from heart failure

Unudurthi SD, Luthra P, Bose RJC, McCarthy J, Kontaridis MI.

COVID-19 vaccinations in patients with inflammatory bowel disease

Kumar A, Quraishi MN, Segal JP, Raine T, Brookes MJ.

Features of Intestinal Disease Associated with COVID-Related Multisystem Inflammatory Syndrome in Children

Sahn B, Eze OP, Edelman MC, Chougar CE, Thomas RM, Schleien CL, Weinstein T.

Endocrinological disorders and inflammatory skin diseases during COVID-19 outbreak. A review of the literature

Marasca C, Fabbrocini G, Barrea L, Capasso G, Di Guida A, Cinelli E, Fontanella G.

Pulmonary vascular endothelial injury and acute pulmonary hypertension caused by COVID-19: the fundamental cause of refractory hypoxemia?

Wang X, Tu Y, Huang B, Li Y, Li Y, Zhang S, Lin Y, Huang L, Zhang W, Luo H.

The Immunology of Multisystem Inflammatory Syndrome in Children with COVID-19

Consiglio CR, Cotugno N, Sardh F, Pou C, Amodio D, Rodriguez L, Tan Z, Zicari S, Ruggiero A, Pascucci GR, Santilli V, Campbell T, Bryceson Y, Eriksson D, Wang J, Marchesi A, Lakshmikanth T, Campana A, Villani A, Rossi P; CACTUS Study Team, Landegren N, Palma P, Brodin P.

The Perfect Storm: COVID-19 Health Disparities in US Blacks

Phillips N, Park IW, Robinson JR, Jones HP.

Lung ultrasound signs and cytokine profile in Covid-19 patients: a case series

Delrio S, Vetrugno L, Orso D, Deana C, D'Andrea N, Bove T.

Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort

Ciurea A, Papagiannoulis E, Bürki K, von Loga I, Micheroli R, Möller B, Rubbert-Roth A, Andor M, Bräm R, Müller A, Dan D, Kyburz D, Distler O, Scherer A, Finckh A.

Inflammatory phenotyping predicts clinical outcome in COVID-19

Burke H, Freeman A, Cellura DC, Stuart BL, Brendish NJ, Poole S, Borca F, Phan HTT, Sheard N, Williams S, Spalluto CM, Staples KJ, Clark TW, Wilkinson TMA; REACT COVID investigators.

The Role of Tocilizumab in Cytokine Storm and Improving Outcomes in COVID-19

Ali A, Kamjani MH, Kesselman MM.

Cytokine storm and COVID-19: a chronicle of pro-inflammatory cytokines

Fara A, Mitrev Z, Rosalia RA, Assas BM.